US9333187B1 - Compositions and methods for the treatment of inflammatory bowel disease - Google Patents
Compositions and methods for the treatment of inflammatory bowel disease Download PDFInfo
- Publication number
- US9333187B1 US9333187B1 US14/834,411 US201514834411A US9333187B1 US 9333187 B1 US9333187 B1 US 9333187B1 US 201514834411 A US201514834411 A US 201514834411A US 9333187 B1 US9333187 B1 US 9333187B1
- Authority
- US
- United States
- Prior art keywords
- compositions
- compound
- formula
- administration
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 144
- 208000022559 Inflammatory bowel disease Diseases 0.000 title claims abstract description 25
- 238000000034 method Methods 0.000 title abstract description 40
- 150000001875 compounds Chemical class 0.000 claims abstract description 68
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 23
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 206010009900 Colitis ulcerative Diseases 0.000 claims abstract description 22
- 201000006704 Ulcerative Colitis Diseases 0.000 claims abstract description 21
- 208000011231 Crohn disease Diseases 0.000 claims abstract description 11
- 239000007924 injection Substances 0.000 claims abstract description 7
- 238000002347 injection Methods 0.000 claims abstract description 7
- 230000004054 inflammatory process Effects 0.000 claims abstract description 6
- 238000007911 parenteral administration Methods 0.000 claims abstract description 6
- 230000000699 topical effect Effects 0.000 claims abstract description 6
- 208000018522 Gastrointestinal disease Diseases 0.000 claims abstract description 5
- 239000006188 syrup Substances 0.000 claims abstract description 4
- 235000020357 syrup Nutrition 0.000 claims abstract description 4
- 206010064147 Gastrointestinal inflammation Diseases 0.000 claims abstract description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims abstract description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims abstract description 3
- 206010003246 arthritis Diseases 0.000 claims abstract description 3
- 208000019425 cirrhosis of liver Diseases 0.000 claims abstract description 3
- 206010021247 idiopathic urticaria Diseases 0.000 claims abstract description 3
- 230000002757 inflammatory effect Effects 0.000 claims abstract description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract description 3
- 239000012453 solvate Substances 0.000 claims abstract 2
- -1 transmucosal Substances 0.000 claims description 19
- 239000003937 drug carrier Substances 0.000 claims description 14
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 230000003111 delayed effect Effects 0.000 claims description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 5
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 4
- 238000013268 sustained release Methods 0.000 claims description 4
- 239000012730 sustained-release form Substances 0.000 claims description 4
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims description 2
- 229960004963 mesalazine Drugs 0.000 claims description 2
- 229940100688 oral solution Drugs 0.000 claims description 2
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 claims 4
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 claims 2
- 229940090949 docosahexaenoic acid Drugs 0.000 claims 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims 2
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims 1
- 229960002446 octanoic acid Drugs 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract description 6
- 238000001990 intravenous administration Methods 0.000 abstract description 5
- 150000004677 hydrates Chemical class 0.000 abstract description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 33
- 239000003814 drug Substances 0.000 description 30
- 201000010099 disease Diseases 0.000 description 27
- 229940079593 drug Drugs 0.000 description 27
- 239000000243 solution Substances 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 27
- 239000002552 dosage form Substances 0.000 description 22
- 239000003826 tablet Substances 0.000 description 21
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 19
- 238000009472 formulation Methods 0.000 description 19
- 239000000463 material Substances 0.000 description 19
- 239000011541 reaction mixture Substances 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 239000013543 active substance Substances 0.000 description 14
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 13
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 12
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 12
- 229920002472 Starch Polymers 0.000 description 11
- 238000000576 coating method Methods 0.000 description 11
- 239000010408 film Substances 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 235000019698 starch Nutrition 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- 0 [2*][1*]C(=O)C1=CC(N[3*][4*])=CC=C1O Chemical compound [2*][1*]C(=O)C1=CC(N[3*][4*])=CC=C1O 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 239000002775 capsule Substances 0.000 description 9
- 239000011248 coating agent Substances 0.000 description 9
- 239000003085 diluting agent Substances 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- 238000000746 purification Methods 0.000 description 9
- 238000003786 synthesis reaction Methods 0.000 description 9
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 8
- 241000282414 Homo sapiens Species 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
- 239000011324 bead Substances 0.000 description 8
- 239000010410 layer Substances 0.000 description 8
- 229920001223 polyethylene glycol Polymers 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 7
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 7
- 239000011230 binding agent Substances 0.000 description 7
- 235000019439 ethyl acetate Nutrition 0.000 description 7
- 239000000945 filler Substances 0.000 description 7
- 239000007788 liquid Substances 0.000 description 7
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
- 239000000843 powder Substances 0.000 description 7
- 239000000651 prodrug Substances 0.000 description 7
- 229940002612 prodrug Drugs 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 6
- 229920001817 Agar Polymers 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 229930006000 Sucrose Natural products 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 235000010419 agar Nutrition 0.000 description 6
- 235000010443 alginic acid Nutrition 0.000 description 6
- 229920000615 alginic acid Polymers 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000002131 composite material Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 6
- 230000000069 prophylactic effect Effects 0.000 description 6
- FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 239000005720 sucrose Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000000454 talc Substances 0.000 description 6
- 235000012222 talc Nutrition 0.000 description 6
- 229910052623 talc Inorganic materials 0.000 description 6
- 239000001993 wax Substances 0.000 description 6
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
- 241000416162 Astragalus gummifer Species 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 5
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 5
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 229920001615 Tragacanth Polymers 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 239000000443 aerosol Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 239000008273 gelatin Substances 0.000 description 5
- 229920000159 gelatin Polymers 0.000 description 5
- 235000019322 gelatine Nutrition 0.000 description 5
- 235000011852 gelatine desserts Nutrition 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 239000000314 lubricant Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000036470 plasma concentration Effects 0.000 description 5
- 235000010487 tragacanth Nutrition 0.000 description 5
- 239000000196 tragacanth Substances 0.000 description 5
- 229940116362 tragacanth Drugs 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 4
- YMFPANVOVFOJRM-OLIXOTBGSA-N C=C(C1=C(OC(=O)C2=CC=CC=C2O)C=CC=C1)C(C)(C)C.CC(=O)NC1=CC=C(OC(C)(C)C)C=C1.CC(=O)N[C@@H](CC(=O)C(C)(C)C)C(=O)O.CC(=O)OC1=CC=CC=C1C(=O)C(C)(C)C.CC(=O)[C@H](CC1=CC(O)=C(O)C=C1)NC(C)(C)C.CC(C)(C)C(=O)C1=CC=CC=C1O.CC(C)(C)N[C@@H](CC(=O)O)C(=O)O.CC(C)(C)OC1=CC=CC=C1C(=O)O.CC(C)(C)OC1=CC=CC=C1C(N)=O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(=O)C(C)(C)C.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)C(C)(C)C.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(C)(C)C.CC1=C2CCC(C)(CCCC(C)C(C)C)OC2=C(C)C(C)=C1OC(=O)C(C)(C)C.CC1=NC=C(CO)C(CNC(C)(C)C)=C1O.[H][C@](O)(C(=O)CCCC(=O)C(C)(C)C)C(C)(C)CO.[H][C@]12NC(=O)N[C@@]1([H])CS[C@H]2CCCCC(=O)C(C)(C)C Chemical compound C=C(C1=C(OC(=O)C2=CC=CC=C2O)C=CC=C1)C(C)(C)C.CC(=O)NC1=CC=C(OC(C)(C)C)C=C1.CC(=O)N[C@@H](CC(=O)C(C)(C)C)C(=O)O.CC(=O)OC1=CC=CC=C1C(=O)C(C)(C)C.CC(=O)[C@H](CC1=CC(O)=C(O)C=C1)NC(C)(C)C.CC(C)(C)C(=O)C1=CC=CC=C1O.CC(C)(C)N[C@@H](CC(=O)O)C(=O)O.CC(C)(C)OC1=CC=CC=C1C(=O)O.CC(C)(C)OC1=CC=CC=C1C(N)=O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(=O)C(C)(C)C.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)C(C)(C)C.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(C)(C)C.CC1=C2CCC(C)(CCCC(C)C(C)C)OC2=C(C)C(C)=C1OC(=O)C(C)(C)C.CC1=NC=C(CO)C(CNC(C)(C)C)=C1O.[H][C@](O)(C(=O)CCCC(=O)C(C)(C)C)C(C)(C)CO.[H][C@]12NC(=O)N[C@@]1([H])CS[C@H]2CCCCC(=O)C(C)(C)C YMFPANVOVFOJRM-OLIXOTBGSA-N 0.000 description 4
- BCGAEORUFVXYGX-UHFFFAOYSA-N CC(C)(C)CCCNC(C)(C)C.CC(C)(C)CCCOC(C)(C)C.CC(C)(C)CCCOCCCC(C)(C)C.CC(C)(C)CCCSCCCC(C)(C)C.CC(C)(C)OCC(O)COC(C)(C)C.CC(C)(C)OCCCNC(=O)C(C)(C)C.CC(C)C(=O)NCCOC(C)(C)C.CC(C)CC(=O)OC(C)C.CC(C)OC(C)C.CC(OC(=O)C(C)C)OC(=O)C(C)C.CN(CCCC(C)(C)C)CCCC(C)(C)C Chemical compound CC(C)(C)CCCNC(C)(C)C.CC(C)(C)CCCOC(C)(C)C.CC(C)(C)CCCOCCCC(C)(C)C.CC(C)(C)CCCSCCCC(C)(C)C.CC(C)(C)OCC(O)COC(C)(C)C.CC(C)(C)OCCCNC(=O)C(C)(C)C.CC(C)C(=O)NCCOC(C)(C)C.CC(C)CC(=O)OC(C)C.CC(C)OC(C)C.CC(OC(=O)C(C)C)OC(=O)C(C)C.CN(CCCC(C)(C)C)CCCC(C)(C)C BCGAEORUFVXYGX-UHFFFAOYSA-N 0.000 description 4
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 4
- 229920001283 Polyalkylene terephthalate Polymers 0.000 description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000012790 adhesive layer Substances 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 235000012216 bentonite Nutrition 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229940126214 compound 3 Drugs 0.000 description 4
- 229940125898 compound 5 Drugs 0.000 description 4
- 235000014113 dietary fatty acids Nutrition 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 235000019441 ethanol Nutrition 0.000 description 4
- 239000000194 fatty acid Substances 0.000 description 4
- 229930195729 fatty acid Natural products 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 235000011187 glycerol Nutrition 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229960004063 propylene glycol Drugs 0.000 description 4
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 238000007920 subcutaneous administration Methods 0.000 description 4
- 239000000829 suppository Substances 0.000 description 4
- HCAJQHYUCKICQH-VPENINKCSA-N 8-Oxo-7,8-dihydro-2'-deoxyguanosine Chemical compound C1=2NC(N)=NC(=O)C=2NC(=O)N1[C@H]1C[C@H](O)[C@@H](CO)O1 HCAJQHYUCKICQH-VPENINKCSA-N 0.000 description 3
- 244000215068 Acacia senegal Species 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- CWVGZZJPUQWGLH-UHFFFAOYSA-N CC(C)(C)C(=O)C(C)(C)C.CC(C)(C)C(=O)CCC(N)C(=O)C(C)(C)C.CC(C)(C)OC(=O)CCC(N)C(=O)OC(C)(C)C.CC(C)(C)OC(=O)CCC(N)C(=O)OC(C)(C)C.CC(C)(C)OC(C)(C)C.CC(C)(C)OCOC(C)(C)C.CC(C)C(=O)C(C)C.CC(C)C(=O)NCCOC(=O)C(C)C.CC(C)C(=O)OC(=O)C(C)(C)C.CC(C)CC(=O)C(C)C.CC(C)OC(C)OC(C)C.CC(OC(C)(C)C)OC(C)(C)C Chemical compound CC(C)(C)C(=O)C(C)(C)C.CC(C)(C)C(=O)CCC(N)C(=O)C(C)(C)C.CC(C)(C)OC(=O)CCC(N)C(=O)OC(C)(C)C.CC(C)(C)OC(=O)CCC(N)C(=O)OC(C)(C)C.CC(C)(C)OC(C)(C)C.CC(C)(C)OCOC(C)(C)C.CC(C)C(=O)C(C)C.CC(C)C(=O)NCCOC(=O)C(C)C.CC(C)C(=O)OC(=O)C(C)(C)C.CC(C)CC(=O)C(C)C.CC(C)OC(C)OC(C)C.CC(OC(C)(C)C)OC(C)(C)C CWVGZZJPUQWGLH-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 3
- 229920002785 Croscarmellose sodium Polymers 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 229920000084 Gum arabic Polymers 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 3
- 240000007472 Leucaena leucocephala Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- LFZAGIJXANFPFN-UHFFFAOYSA-N N-[3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-thiophen-2-ylpropyl]acetamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CCC(C=1SC=CC=1)NC(C)=O)C LFZAGIJXANFPFN-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 235000010489 acacia gum Nutrition 0.000 description 3
- 239000000205 acacia gum Substances 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000001070 adhesive effect Effects 0.000 description 3
- 239000000783 alginic acid Substances 0.000 description 3
- 229960001126 alginic acid Drugs 0.000 description 3
- 150000004781 alginic acids Chemical class 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 239000000440 bentonite Substances 0.000 description 3
- 229910000278 bentonite Inorganic materials 0.000 description 3
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940110456 cocoa butter Drugs 0.000 description 3
- 235000019868 cocoa butter Nutrition 0.000 description 3
- 206010009887 colitis Diseases 0.000 description 3
- 210000001072 colon Anatomy 0.000 description 3
- 229940125773 compound 10 Drugs 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 238000013265 extended release Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000003925 fat Substances 0.000 description 3
- 235000019197 fats Nutrition 0.000 description 3
- 239000007903 gelatin capsule Substances 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 125000005456 glyceride group Chemical group 0.000 description 3
- 239000000416 hydrocolloid Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 230000002503 metabolic effect Effects 0.000 description 3
- 238000001690 micro-dialysis Methods 0.000 description 3
- 239000003182 parenteral nutrition solution Substances 0.000 description 3
- 239000006072 paste Substances 0.000 description 3
- 239000000312 peanut oil Substances 0.000 description 3
- 235000010987 pectin Nutrition 0.000 description 3
- 229920001277 pectin Polymers 0.000 description 3
- 239000001814 pectin Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 235000021251 pulses Nutrition 0.000 description 3
- 239000011342 resin composition Substances 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 239000008159 sesame oil Substances 0.000 description 3
- 235000011803 sesame oil Nutrition 0.000 description 3
- 239000000741 silica gel Substances 0.000 description 3
- 229910002027 silica gel Inorganic materials 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 229920003109 sodium starch glycolate Polymers 0.000 description 3
- 239000008109 sodium starch glycolate Substances 0.000 description 3
- 229940079832 sodium starch glycolate Drugs 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000002600 sunflower oil Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 description 2
- DBTMGCOVALSLOR-DEVYUCJPSA-N (2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](CO)O[C@H](O)[C@@H]2O)O)O[C@H](CO)[C@H]1O DBTMGCOVALSLOR-DEVYUCJPSA-N 0.000 description 2
- QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- FEBUJFMRSBAMES-UHFFFAOYSA-N 2-[(2-{[3,5-dihydroxy-2-(hydroxymethyl)-6-phosphanyloxan-4-yl]oxy}-3,5-dihydroxy-6-({[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}methyl)oxan-4-yl)oxy]-3,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl phosphinite Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(OC2C(C(OP)C(O)C(CO)O2)O)C(O)C(OC2C(C(CO)OC(P)C2O)O)O1 FEBUJFMRSBAMES-UHFFFAOYSA-N 0.000 description 2
- BWGRDBSNKQABCB-UHFFFAOYSA-N 4,4-difluoro-N-[3-[3-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)-8-azabicyclo[3.2.1]octan-8-yl]-1-thiophen-2-ylpropyl]cyclohexane-1-carboxamide Chemical compound CC(C)C1=NN=C(C)N1C1CC2CCC(C1)N2CCC(NC(=O)C1CCC(F)(F)CC1)C1=CC=CS1 BWGRDBSNKQABCB-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- 239000005995 Aluminium silicate Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- BUGGJSBCYZBZRS-LOFBBATRSA-N CC(=O)[C@@H](N)CCCNC(=N)NC(C)(C)C.CC(C)(C)C(=O)C1=CC=C(N)C=C1O.CC(C)(C)C(=O)C1=CC=CN=C1.CC(C)(C)C(=O)CC(O)C[N+](C)(C)C.CC(C)(C)C(=O)[C@@H](N)CC1=CNC2=C1C=C(O)C=C2.CC(C)(C)C(=O)[C@@H](N)CCCNC(=N)N.CC(C)(C)CCCC1=CNC2=CC=C(O)C=C12.CC(C)(C)NC(=O)C1=CC=CN=C1.CC(C)(C)OC(=O)CCCC1=CC=CC=C1.CC(C)(C)OCCC1=CC=C(O)C(O)=C1.CC/C=C\CC(=O)C(C)(C)C.CC/C=C\CC(C)(C)C(=O)C(C)C.CCCCCCCC(=O)OC(C)(C)C.CN1C=NC2=C1C(=O)N(CCCCC(=O)C(C)(C)C)C(=O)N2C Chemical compound CC(=O)[C@@H](N)CCCNC(=N)NC(C)(C)C.CC(C)(C)C(=O)C1=CC=C(N)C=C1O.CC(C)(C)C(=O)C1=CC=CN=C1.CC(C)(C)C(=O)CC(O)C[N+](C)(C)C.CC(C)(C)C(=O)[C@@H](N)CC1=CNC2=C1C=C(O)C=C2.CC(C)(C)C(=O)[C@@H](N)CCCNC(=N)N.CC(C)(C)CCCC1=CNC2=CC=C(O)C=C12.CC(C)(C)NC(=O)C1=CC=CN=C1.CC(C)(C)OC(=O)CCCC1=CC=CC=C1.CC(C)(C)OCCC1=CC=C(O)C(O)=C1.CC/C=C\CC(=O)C(C)(C)C.CC/C=C\CC(C)(C)C(=O)C(C)C.CCCCCCCC(=O)OC(C)(C)C.CN1C=NC2=C1C(=O)N(CCCCC(=O)C(C)(C)C)C(=O)N2C BUGGJSBCYZBZRS-LOFBBATRSA-N 0.000 description 2
- WDORFRVMKNFLJQ-IASQAFRTSA-N CC(=O)[C@@H](N)CCCNC(=N)NC(C)(C)C.CC(C)(C)C(=O)C1=CC=C(N)C=C1O.CC(C)(C)C(=O)C1=CC=CN=C1.CC(C)(C)C(=O)CC(O)C[N+](C)(C)C.CC(C)(C)C(=O)[C@@H](N)CC1=CNC2=C1C=C(O)C=C2.CC(C)(C)C(=O)[C@@H](N)CCCNC(=N)N.CC(C)(C)CCCC1=CNC2=CC=C(O)C=C12.CC(C)(C)NC(=O)C1=CC=CN=C1.CC/C=C\CC(=O)C(C)(C)C.CC/C=C\CC(C)(C)C(=O)C(C)C.CN1C=NC2=C1C(=O)N(CCCCC(=O)C(C)(C)C)C(=O)N2C Chemical compound CC(=O)[C@@H](N)CCCNC(=N)NC(C)(C)C.CC(C)(C)C(=O)C1=CC=C(N)C=C1O.CC(C)(C)C(=O)C1=CC=CN=C1.CC(C)(C)C(=O)CC(O)C[N+](C)(C)C.CC(C)(C)C(=O)[C@@H](N)CC1=CNC2=C1C=C(O)C=C2.CC(C)(C)C(=O)[C@@H](N)CCCNC(=N)N.CC(C)(C)CCCC1=CNC2=CC=C(O)C=C12.CC(C)(C)NC(=O)C1=CC=CN=C1.CC/C=C\CC(=O)C(C)(C)C.CC/C=C\CC(C)(C)C(=O)C(C)C.CN1C=NC2=C1C(=O)N(CCCCC(=O)C(C)(C)C)C(=O)N2C WDORFRVMKNFLJQ-IASQAFRTSA-N 0.000 description 2
- CHYBPWFDIBSABR-UHFFFAOYSA-N CC(C)(C)C(=O)C(C)(C)C.CC(C)(C)C(=O)CCC(N)C(=O)C(C)(C)C.CC(C)(C)C(=O)OC(=O)C(C)(C)C.CC(C)(C)CC(=O)C(C)(C)C.CC(C)(C)OC(=O)CCC(N)C(=O)OC(C)(C)C.CC(C)(C)OC(C)(C)C.CC(C)(C)OCOC(C)(C)C.CC(OC(C)(C)C)OC(C)(C)C Chemical compound CC(C)(C)C(=O)C(C)(C)C.CC(C)(C)C(=O)CCC(N)C(=O)C(C)(C)C.CC(C)(C)C(=O)OC(=O)C(C)(C)C.CC(C)(C)CC(=O)C(C)(C)C.CC(C)(C)OC(=O)CCC(N)C(=O)OC(C)(C)C.CC(C)(C)OC(C)(C)C.CC(C)(C)OCOC(C)(C)C.CC(OC(C)(C)C)OC(C)(C)C CHYBPWFDIBSABR-UHFFFAOYSA-N 0.000 description 2
- UDNOKRFOTHMSTI-UHFFFAOYSA-N CC(C)(C)CC(=O)OC(C)(C)C.CC(C)(C)CCCNC(C)(C)C.CC(C)(C)CCCOC(C)(C)C.CC(C)(C)CCCOCCCC(C)(C)C.CC(C)(C)CCCSCCCC(C)(C)C.CC(C)(C)OCC(O)COC(C)(C)C.CC(C)(C)OCCCNC(=O)C(C)(C)C.CC(C)(C)OCCNC(=O)C(C)(C)C.CC(OC(=O)C(C)(C)C)OC(=O)C(C)(C)C.CN(CCCC(C)(C)C)CCCC(C)(C)C Chemical compound CC(C)(C)CC(=O)OC(C)(C)C.CC(C)(C)CCCNC(C)(C)C.CC(C)(C)CCCOC(C)(C)C.CC(C)(C)CCCOCCCC(C)(C)C.CC(C)(C)CCCSCCCC(C)(C)C.CC(C)(C)OCC(O)COC(C)(C)C.CC(C)(C)OCCCNC(=O)C(C)(C)C.CC(C)(C)OCCNC(=O)C(C)(C)C.CC(OC(=O)C(C)(C)C)OC(=O)C(C)(C)C.CN(CCCC(C)(C)C)CCCC(C)(C)C UDNOKRFOTHMSTI-UHFFFAOYSA-N 0.000 description 2
- 235000017399 Caesalpinia tinctoria Nutrition 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 229920002101 Chitin Polymers 0.000 description 2
- 229920001661 Chitosan Polymers 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229920000926 Galactomannan Polymers 0.000 description 2
- 241000206672 Gelidium Species 0.000 description 2
- 229920002148 Gellan gum Polymers 0.000 description 2
- 229920002907 Guar gum Polymers 0.000 description 2
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 229920001543 Laminarin Polymers 0.000 description 2
- 239000005717 Laminarin Substances 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229920002774 Maltodextrin Polymers 0.000 description 2
- 239000005913 Maltodextrin Substances 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 2
- 235000019483 Peanut oil Nutrition 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 229920002305 Schizophyllan Polymers 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 235000019486 Sunflower oil Nutrition 0.000 description 2
- 241000388430 Tara Species 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009102 absorption Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- TUCNEACPLKLKNU-UHFFFAOYSA-N acetyl Chemical compound C[C]=O TUCNEACPLKLKNU-UHFFFAOYSA-N 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
- 235000012211 aluminium silicate Nutrition 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229910000019 calcium carbonate Inorganic materials 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 229940105329 carboxymethylcellulose Drugs 0.000 description 2
- 235000010418 carrageenan Nutrition 0.000 description 2
- 229920001525 carrageenan Polymers 0.000 description 2
- 239000000679 carrageenan Substances 0.000 description 2
- 229940113118 carrageenan Drugs 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 239000007891 compressed tablet Substances 0.000 description 2
- 239000002285 corn oil Substances 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000002385 cottonseed oil Substances 0.000 description 2
- 229920006037 cross link polymer Polymers 0.000 description 2
- 239000013058 crude material Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 230000008378 epithelial damage Effects 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 239000011888 foil Substances 0.000 description 2
- 235000010417 guar gum Nutrition 0.000 description 2
- 239000000665 guar gum Substances 0.000 description 2
- 229960002154 guar gum Drugs 0.000 description 2
- 229920001477 hydrophilic polymer Polymers 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 2
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 229940035034 maltodextrin Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 235000018343 nutrient deficiency Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920000233 poly(alkylene oxides) Polymers 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920001515 polyalkylene glycol Polymers 0.000 description 2
- 239000004645 polyester resin Substances 0.000 description 2
- 229920001225 polyester resin Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000003380 propellant Substances 0.000 description 2
- 235000013772 propylene glycol Nutrition 0.000 description 2
- 210000000664 rectum Anatomy 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 150000004760 silicates Chemical class 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 235000009518 sodium iodide Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 239000008247 solid mixture Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 239000003549 soybean oil Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 229920001169 thermoplastic Polymers 0.000 description 2
- 239000004416 thermosoftening plastic Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- 238000013271 transdermal drug delivery Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 229940086542 triethylamine Drugs 0.000 description 2
- DCXXMTOCNZCJGO-UHFFFAOYSA-N tristearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 description 2
- 239000003039 volatile agent Substances 0.000 description 2
- 229920003176 water-insoluble polymer Polymers 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 2
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- UVNPEUJXKZFWSJ-LMTQTHQJSA-N (R)-N-[(4S)-8-[6-amino-5-[(3,3-difluoro-2-oxo-1H-pyrrolo[2,3-b]pyridin-4-yl)sulfanyl]pyrazin-2-yl]-2-oxa-8-azaspiro[4.5]decan-4-yl]-2-methylpropane-2-sulfinamide Chemical compound CC(C)(C)[S@@](=O)N[C@@H]1COCC11CCN(CC1)c1cnc(Sc2ccnc3NC(=O)C(F)(F)c23)c(N)n1 UVNPEUJXKZFWSJ-LMTQTHQJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- JNODDICFTDYODH-UHFFFAOYSA-N 2-hydroxytetrahydrofuran Chemical compound OC1CCCO1 JNODDICFTDYODH-UHFFFAOYSA-N 0.000 description 1
- WDBQJSCPCGTAFG-QHCPKHFHSA-N 4,4-difluoro-N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclohexane-1-carboxamide Chemical compound FC1(CCC(CC1)C(=O)N[C@@H](CCN1CCC(CC1)N1C(=NN=C1C)C(C)C)C=1C=NC=CC=1)F WDBQJSCPCGTAFG-QHCPKHFHSA-N 0.000 description 1
- GJCOSYZMQJWQCA-UHFFFAOYSA-N 9H-xanthene Chemical compound C1=CC=C2CC3=CC=CC=C3OC2=C1 GJCOSYZMQJWQCA-UHFFFAOYSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- VTNUWJIUMRGSSL-HNSJWGTKSA-N BrB(Br)Br.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(N)C=C1O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(N)C=C1OC.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(NC)C=C1O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(NC)C=C1OC.CCCCCCCC(=O)O.CCCCCCCC(=O)OC(=O)C1=C/C(=N/C)C=CC1=O.CCCCCCCC(=O)OC(=O)C1=C/C(=N/C)C=CC1=O.CCCCCCCC(=O)OC(=O)C1=CC=CC=C1O.NC1=CC(O)=C(ClC=O)C=C1.NC1=CC(O)=C(OC=O)C=C1.O=C(O)C1=CC=CC=C1O.O=C(OCl)C1=CC=CC=C1O.O=S(Cl)Cl.O=S(Cl)Cl Chemical compound BrB(Br)Br.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(N)C=C1O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(N)C=C1OC.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(NC)C=C1O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(NC)C=C1OC.CCCCCCCC(=O)O.CCCCCCCC(=O)OC(=O)C1=C/C(=N/C)C=CC1=O.CCCCCCCC(=O)OC(=O)C1=C/C(=N/C)C=CC1=O.CCCCCCCC(=O)OC(=O)C1=CC=CC=C1O.NC1=CC(O)=C(ClC=O)C=C1.NC1=CC(O)=C(OC=O)C=C1.O=C(O)C1=CC=CC=C1O.O=C(OCl)C1=CC=CC=C1O.O=S(Cl)Cl.O=S(Cl)Cl VTNUWJIUMRGSSL-HNSJWGTKSA-N 0.000 description 1
- SSHHKLGHCPTPNT-JTTZUHECSA-N BrB(Br)Br.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(NC)C=C1O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(NC)C=C1OC.CCCCCCCC(=O)OC(=O)C1=C/C(=N/C)C=CC1=O.CCCCCCCC(=O)OC(=O)C1=C/C(=N/C)C=CC1=O Chemical compound BrB(Br)Br.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(NC)C=C1O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(NC)C=C1OC.CCCCCCCC(=O)OC(=O)C1=C/C(=N/C)C=CC1=O.CCCCCCCC(=O)OC(=O)C1=C/C(=N/C)C=CC1=O SSHHKLGHCPTPNT-JTTZUHECSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- WPFUWSMYVCYQTN-KSSWDJKLSA-N C=C(C1=C(OC(=O)C2=CC=CC=C2O)C=CC=C1)C(C)(C)C.CC(=O)N[C@@H](CC(=O)C(C)(C)C)C(=O)O.CC(=O)OC1=CC=CC=C1C(=O)C(C)(C)C.CC(=O)[C@H](CC1=CC(O)=C(O)C=C1)NC(C)(C)C.CC(C)(C)C(=O)C1=CC=CC=C1O.CC(C)(C)OC1=CC=CC=C1C(=O)O.CC(C)(C)OC1=CC=CC=C1C(N)=O.CC1=C2CCC(C)(CCCC(C)C(C)C)OC2=C(C)C(C)=C1OC(=O)C(C)(C)C.CC1=CC=C(OC(C)(C)C)C=C1.CC1=NC=C(CO)C(CNC(C)(C)C)=C1O Chemical compound C=C(C1=C(OC(=O)C2=CC=CC=C2O)C=CC=C1)C(C)(C)C.CC(=O)N[C@@H](CC(=O)C(C)(C)C)C(=O)O.CC(=O)OC1=CC=CC=C1C(=O)C(C)(C)C.CC(=O)[C@H](CC1=CC(O)=C(O)C=C1)NC(C)(C)C.CC(C)(C)C(=O)C1=CC=CC=C1O.CC(C)(C)OC1=CC=CC=C1C(=O)O.CC(C)(C)OC1=CC=CC=C1C(N)=O.CC1=C2CCC(C)(CCCC(C)C(C)C)OC2=C(C)C(C)=C1OC(=O)C(C)(C)C.CC1=CC=C(OC(C)(C)C)C=C1.CC1=NC=C(CO)C(CNC(C)(C)C)=C1O WPFUWSMYVCYQTN-KSSWDJKLSA-N 0.000 description 1
- LJYFPAIIDCWEKS-WQJAQNBVSA-N C=C(O)[C@@H](N)CCCCNC(C)(C)C.CC(C)(C)C(=O)C1=CC(O)=C(O)C(O)=C1.CC(C)(C)OC(=O)C(N)CCC(=O)O.CC(C)(C)OC(=O)CCCC1=CC=CC=C1.CC(C)(C)OC(=O)[C@@H](N)CC1=CC=C(O)C=C1.CC(S)C(=O)CCC(=O)OC(C)(C)C.CCCCCCCC(=O)C(C)(C)C.CCCCCCCC(=O)OC(C)(C)C.COC(=O)/C=C/C(=O)OC(C)(C)C Chemical compound C=C(O)[C@@H](N)CCCCNC(C)(C)C.CC(C)(C)C(=O)C1=CC(O)=C(O)C(O)=C1.CC(C)(C)OC(=O)C(N)CCC(=O)O.CC(C)(C)OC(=O)CCCC1=CC=CC=C1.CC(C)(C)OC(=O)[C@@H](N)CC1=CC=C(O)C=C1.CC(S)C(=O)CCC(=O)OC(C)(C)C.CCCCCCCC(=O)C(C)(C)C.CCCCCCCC(=O)OC(C)(C)C.COC(=O)/C=C/C(=O)OC(C)(C)C LJYFPAIIDCWEKS-WQJAQNBVSA-N 0.000 description 1
- HKETXGBDNKFTHV-KMEFSXFQSA-N CC(=O)CCCCC(C)(C)C.CC(C)(C)C(=O)C1=CC(=O)C2=C(C=CC=C2O)O1.CC(C)(C)C(=O)[C@@H](N)CS.CC(C)(C)OC(=O)/C=C/C(=O)O.CC(C)(C)OC(=O)CCCN.CC(C)(C)OCCC1=CC=C(O)C(O)=C1.COC(=O)/C=C/C(=O)OCC(C)(C)C.[H][C@@](CS)(NC(C)=O)C(=C)C(C)(C)C.[H][C@@]1(CCCCC(=O)C(C)(C)C)CCSS1.[H][C@@]1(CCCCC(=O)OC(C)(C)C)CCSS1 Chemical compound CC(=O)CCCCC(C)(C)C.CC(C)(C)C(=O)C1=CC(=O)C2=C(C=CC=C2O)O1.CC(C)(C)C(=O)[C@@H](N)CS.CC(C)(C)OC(=O)/C=C/C(=O)O.CC(C)(C)OC(=O)CCCN.CC(C)(C)OCCC1=CC=C(O)C(O)=C1.COC(=O)/C=C/C(=O)OCC(C)(C)C.[H][C@@](CS)(NC(C)=O)C(=C)C(C)(C)C.[H][C@@]1(CCCCC(=O)C(C)(C)C)CCSS1.[H][C@@]1(CCCCC(=O)OC(C)(C)C)CCSS1 HKETXGBDNKFTHV-KMEFSXFQSA-N 0.000 description 1
- QZVRGZMGASKPGB-QPAGKBQSSA-N CC(=O)[C@@H](N)CCCNC(=N)NC(C)(C)C.CC(=O)[C@H](CC(=O)O)NC(C)(C)C.CC(C)(C)C(=O)C1=CC=C(N)C=C1O.CC(C)(C)C(=O)C1=CC=CN=C1.CC(C)(C)C(=O)CC(O)C[N+](C)(C)C.CC(C)(C)C(=O)[C@@H](N)CC1=CNC2=C1C=C(O)C=C2.CC(C)(C)CCCC1=CNC2=CC=C(O)C=C12.CN1C=NC2=C1C(=O)N(CCCCC(=O)C(C)(C)C)C(=O)N2C.[H][C@]12NC(=O)N[C@@]1([H])CS[C@H]2CCCCC(=O)C(C)(C)C Chemical compound CC(=O)[C@@H](N)CCCNC(=N)NC(C)(C)C.CC(=O)[C@H](CC(=O)O)NC(C)(C)C.CC(C)(C)C(=O)C1=CC=C(N)C=C1O.CC(C)(C)C(=O)C1=CC=CN=C1.CC(C)(C)C(=O)CC(O)C[N+](C)(C)C.CC(C)(C)C(=O)[C@@H](N)CC1=CNC2=C1C=C(O)C=C2.CC(C)(C)CCCC1=CNC2=CC=C(O)C=C12.CN1C=NC2=C1C(=O)N(CCCCC(=O)C(C)(C)C)C(=O)N2C.[H][C@]12NC(=O)N[C@@]1([H])CS[C@H]2CCCCC(=O)C(C)(C)C QZVRGZMGASKPGB-QPAGKBQSSA-N 0.000 description 1
- TYJFWNMZEURIKL-UHFFFAOYSA-N CC(C)(C)C(=O)C(C)(C)C.CC(C)(C)C(=O)CCC(N)C(=O)C(C)(C)C.CC(C)(C)OC(=O)CCC(N)C(=O)OC(C)(C)C.CC(C)(C)OC(=O)CCC(N)C(=O)OC(C)(C)C.CC(C)(C)OC(C)(C)C.CC(C)(C)OCOC(C)(C)C.CC(C)C(=O)C(C)C.CC(C)C(=O)NCCOC(=O)C(C)C.CC(C)C(=O)OC(=O)C(C)C.CC(C)CC(=O)C(C)C.CC(C)OC(C)OC(C)C.CC(OC(C)(C)C)OC(C)(C)C Chemical compound CC(C)(C)C(=O)C(C)(C)C.CC(C)(C)C(=O)CCC(N)C(=O)C(C)(C)C.CC(C)(C)OC(=O)CCC(N)C(=O)OC(C)(C)C.CC(C)(C)OC(=O)CCC(N)C(=O)OC(C)(C)C.CC(C)(C)OC(C)(C)C.CC(C)(C)OCOC(C)(C)C.CC(C)C(=O)C(C)C.CC(C)C(=O)NCCOC(=O)C(C)C.CC(C)C(=O)OC(=O)C(C)C.CC(C)CC(=O)C(C)C.CC(C)OC(C)OC(C)C.CC(OC(C)(C)C)OC(C)(C)C TYJFWNMZEURIKL-UHFFFAOYSA-N 0.000 description 1
- LHBJUFQZEVROJF-WVAYQTRWSA-N CC(C)(C)C(=O)C1=C(O)C=CC(N)=C1.CC(C)(C)C(=O)[C@@H](N)CS.CC(C)(C)CCCCC(=O)O.CC(C)(C)NCCCC[C@H](N)C(=O)O.CC(C)(C)OC(=O)/C=C/C(=O)O.CC(C)(C)OC(=O)C(N)CCC(=O)O.CC(C)(C)OC(=O)CCCN.CC(C)(C)OC(=O)[C@@H](N)CC1=CC=C(O)C=C1.CC(C)C(=O)C1=CC(=O)C2=C(C=CC=C2O)O1.CC(S)C(=O)CCC(=O)OC(C)(C)C.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(=O)OC(C)(C)C.CC1=C(O)C(O)=CC(C(=O)C(C)(C)C)=C1.COC(=O)/C=C/C(=O)OC(C)(C)C.COC(=O)/C=C/C(=O)OCC(C)(C)C.[H][C@@](CS)(NC(C)=O)C(=C)C(C)(C)C.[H][C@@]1(CCCCC(=O)C(C)(C)C)CCSS1.[H][C@@]1(CCCCC(=O)OC(C)(C)C)CCSS1 Chemical compound CC(C)(C)C(=O)C1=C(O)C=CC(N)=C1.CC(C)(C)C(=O)[C@@H](N)CS.CC(C)(C)CCCCC(=O)O.CC(C)(C)NCCCC[C@H](N)C(=O)O.CC(C)(C)OC(=O)/C=C/C(=O)O.CC(C)(C)OC(=O)C(N)CCC(=O)O.CC(C)(C)OC(=O)CCCN.CC(C)(C)OC(=O)[C@@H](N)CC1=CC=C(O)C=C1.CC(C)C(=O)C1=CC(=O)C2=C(C=CC=C2O)O1.CC(S)C(=O)CCC(=O)OC(C)(C)C.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(=O)OC(C)(C)C.CC1=C(O)C(O)=CC(C(=O)C(C)(C)C)=C1.COC(=O)/C=C/C(=O)OC(C)(C)C.COC(=O)/C=C/C(=O)OCC(C)(C)C.[H][C@@](CS)(NC(C)=O)C(=C)C(C)(C)C.[H][C@@]1(CCCCC(=O)C(C)(C)C)CCSS1.[H][C@@]1(CCCCC(=O)OC(C)(C)C)CCSS1 LHBJUFQZEVROJF-WVAYQTRWSA-N 0.000 description 1
- MLKPNYMRQAZEPN-OJFXEMLTSA-N CC(C)(C)C(=O)C1=C(O)C=CC(N)=C1.CC(C)(C)CCCCC(=O)O.CC(C)(C)NCCCC[C@H](N)C(=O)O.CC(C)(C)OC(=O)/C=C/C(=O)O.CC(C)(C)OC(=O)C(N)CCC(=O)O.CC(C)(C)OC(=O)CCCC1=CC=CC=C1.CC(C)(C)OC(=O)CCCN.CC(C)(C)OC(=O)[C@@H](N)CC1=CC=C(O)C=C1.CC(C)(C)OCCC1=CC=C(O)C(O)=C1.CC(C)C(=O)C1=CC(=O)C2=C(C=CC=C2O)O1.CC(C)C(=O)[C@@H](N)CS.CC(S)C(=O)CCC(=O)OC(C)(C)C.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(=O)OC(C)(C)C.CC1=C(O)C(O)=CC(C(=O)C(C)C)=C1.CCCCCCCC(=O)OC(C)(C)C.COC(=O)/C=C/C(=O)OC(C)(C)C.COC(=O)/C=C/C(=O)OCC(C)(C)C.[H][C@@](CS)(NC(C)=O)C(=C)C(C)C.[H][C@@]1(CCCCC(=O)C(C)C)CCSS1.[H][C@@]1(CCCCC(=O)OC(C)(C)C)CCSS1 Chemical compound CC(C)(C)C(=O)C1=C(O)C=CC(N)=C1.CC(C)(C)CCCCC(=O)O.CC(C)(C)NCCCC[C@H](N)C(=O)O.CC(C)(C)OC(=O)/C=C/C(=O)O.CC(C)(C)OC(=O)C(N)CCC(=O)O.CC(C)(C)OC(=O)CCCC1=CC=CC=C1.CC(C)(C)OC(=O)CCCN.CC(C)(C)OC(=O)[C@@H](N)CC1=CC=C(O)C=C1.CC(C)(C)OCCC1=CC=C(O)C(O)=C1.CC(C)C(=O)C1=CC(=O)C2=C(C=CC=C2O)O1.CC(C)C(=O)[C@@H](N)CS.CC(S)C(=O)CCC(=O)OC(C)(C)C.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(=O)OC(C)(C)C.CC1=C(O)C(O)=CC(C(=O)C(C)C)=C1.CCCCCCCC(=O)OC(C)(C)C.COC(=O)/C=C/C(=O)OC(C)(C)C.COC(=O)/C=C/C(=O)OCC(C)(C)C.[H][C@@](CS)(NC(C)=O)C(=C)C(C)C.[H][C@@]1(CCCCC(=O)C(C)C)CCSS1.[H][C@@]1(CCCCC(=O)OC(C)(C)C)CCSS1 MLKPNYMRQAZEPN-OJFXEMLTSA-N 0.000 description 1
- SRUPAXIHTNQQQU-JCONVHQTSA-N CC(C)(C)C(=O)C1=C(O)C=CC(N)=C1.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(=O)C(C)(C)C.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(=O)OC(C)(C)C.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)C(C)(C)C.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(C)(C)C.[H][C@](O)(C(=O)CCCC(=O)C(C)(C)C)C(C)(C)CO Chemical compound CC(C)(C)C(=O)C1=C(O)C=CC(N)=C1.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(=O)C(C)(C)C.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(=O)OC(C)(C)C.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)C(C)(C)C.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(C)(C)C.[H][C@](O)(C(=O)CCCC(=O)C(C)(C)C)C(C)(C)CO SRUPAXIHTNQQQU-JCONVHQTSA-N 0.000 description 1
- VOCZHUGVWQTSGG-PERRORBGSA-N CC(C)(C)C(=O)C1=CC(=O)C2=C(C=CC=C2O)O1.CC(C)(C)C(=O)[C@@H](N)CS.CC(C)(C)CCCCC(=O)O.CC(C)(C)NCCCC[C@H](N)C(=O)O.CC(C)(C)OC(=O)/C=C/C(=O)O.CC(C)(C)OC(=O)C(N)CCC(=O)O.CC(C)(C)OC(=O)CCCC1=CC=CC=C1.CC(C)(C)OC(=O)CCCN.CC(C)(C)OC(=O)[C@@H](N)CC1=CC=C(O)C=C1.CC(C)(C)OCCC1=CC=C(O)C(O)=C1.CC(C)C(=O)C1=C(O)C=CC(N)=C1.CC(S)C(=O)CCC(=O)OC(C)(C)C.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(=O)OC(C)(C)C.CC1=C(O)C(O)=CC(C(=O)C(C)(C)C)=C1.CCCCCCCC(=O)OC(C)(C)C.COC(=O)/C=C/C(=O)OC(C)(C)C.COC(=O)/C=C/C(=O)OCC(C)(C)C.[H][C@@](CS)(NC(C)=O)C(=C)C(C)C.[H][C@@]1(CCCCC(=O)C(C)C)CCSS1.[H][C@@]1(CCCCC(=O)OC(C)(C)C)CCSS1 Chemical compound CC(C)(C)C(=O)C1=CC(=O)C2=C(C=CC=C2O)O1.CC(C)(C)C(=O)[C@@H](N)CS.CC(C)(C)CCCCC(=O)O.CC(C)(C)NCCCC[C@H](N)C(=O)O.CC(C)(C)OC(=O)/C=C/C(=O)O.CC(C)(C)OC(=O)C(N)CCC(=O)O.CC(C)(C)OC(=O)CCCC1=CC=CC=C1.CC(C)(C)OC(=O)CCCN.CC(C)(C)OC(=O)[C@@H](N)CC1=CC=C(O)C=C1.CC(C)(C)OCCC1=CC=C(O)C(O)=C1.CC(C)C(=O)C1=C(O)C=CC(N)=C1.CC(S)C(=O)CCC(=O)OC(C)(C)C.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(=O)OC(C)(C)C.CC1=C(O)C(O)=CC(C(=O)C(C)(C)C)=C1.CCCCCCCC(=O)OC(C)(C)C.COC(=O)/C=C/C(=O)OC(C)(C)C.COC(=O)/C=C/C(=O)OCC(C)(C)C.[H][C@@](CS)(NC(C)=O)C(=C)C(C)C.[H][C@@]1(CCCCC(=O)C(C)C)CCSS1.[H][C@@]1(CCCCC(=O)OC(C)(C)C)CCSS1 VOCZHUGVWQTSGG-PERRORBGSA-N 0.000 description 1
- QSBZMHJNVYRWLL-RQEITZDASA-N CC(C)(C)C(=O)[C@@H](N)CCCNC(=N)N.CC(C)(C)NC(=O)C1=CC=CN=C1.CC/C=C\CC(=O)C(C)(C)C.CC/C=C\CC(C)(C)C(=O)C(C)C Chemical compound CC(C)(C)C(=O)[C@@H](N)CCCNC(=N)N.CC(C)(C)NC(=O)C1=CC=CN=C1.CC/C=C\CC(=O)C(C)(C)C.CC/C=C\CC(C)(C)C(=O)C(C)C QSBZMHJNVYRWLL-RQEITZDASA-N 0.000 description 1
- PDTILFHDTIPDJA-YUPAMOPKSA-N CC(C)(C)C(=O)[C@@H](N)CS.CC(C)(C)CCCCC(=O)O.CC(C)(C)NCCCC[C@H](N)C(=O)O.CC(C)(C)OC(=O)/C=C/C(=O)O.CC(C)(C)OC(=O)C(N)CCC(=O)O.CC(C)(C)OC(=O)CCCN.CC(C)(C)OC(=O)[C@@H](N)CC1=CC=C(O)C=C1.CC(C)C(=O)C1=C(O)C=CC(N)=C1.CC(C)C(=O)C1=CC(=O)C2=C(C=CC=C2O)O1.CC(S)C(=O)CCC(=O)OC(C)(C)C.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(=O)OC(C)(C)C.CC1=C(O)C(O)=CC(C(=O)C(C)(C)C)=C1.COC(=O)/C=C/C(=O)OC(C)(C)C.COC(=O)/C=C/C(=O)OCC(C)(C)C.[H][C@@](CS)(NC(C)=O)C(=C)C(C)C.[H][C@@]1(CCCCC(=O)C(C)C)CCSS1.[H][C@@]1(CCCCC(=O)OC(C)(C)C)CCSS1 Chemical compound CC(C)(C)C(=O)[C@@H](N)CS.CC(C)(C)CCCCC(=O)O.CC(C)(C)NCCCC[C@H](N)C(=O)O.CC(C)(C)OC(=O)/C=C/C(=O)O.CC(C)(C)OC(=O)C(N)CCC(=O)O.CC(C)(C)OC(=O)CCCN.CC(C)(C)OC(=O)[C@@H](N)CC1=CC=C(O)C=C1.CC(C)C(=O)C1=C(O)C=CC(N)=C1.CC(C)C(=O)C1=CC(=O)C2=C(C=CC=C2O)O1.CC(S)C(=O)CCC(=O)OC(C)(C)C.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(=O)OC(C)(C)C.CC1=C(O)C(O)=CC(C(=O)C(C)(C)C)=C1.COC(=O)/C=C/C(=O)OC(C)(C)C.COC(=O)/C=C/C(=O)OCC(C)(C)C.[H][C@@](CS)(NC(C)=O)C(=C)C(C)C.[H][C@@]1(CCCCC(=O)C(C)C)CCSS1.[H][C@@]1(CCCCC(=O)OC(C)(C)C)CCSS1 PDTILFHDTIPDJA-YUPAMOPKSA-N 0.000 description 1
- KAHRXSFEWZITEC-QZCMPJQNSA-N CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(=O)OC(=O)C1=C(O)C=C(N/N=C2\C=CC(=O)C(C(=O)OC(=O)CCCCCCC)=C2)C=C1 Chemical compound CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(=O)OC(=O)C1=C(O)C=C(N/N=C2\C=CC(=O)C(C(=O)OC(=O)CCCCCCC)=C2)C=C1 KAHRXSFEWZITEC-QZCMPJQNSA-N 0.000 description 1
- SUJNDJFCLSMIIR-ABLNXSRISA-N CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(=O)OC(=O)C1=CC(NC(=O)C2=C(O)C=CC(N)=C2)=CC=C1O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(=O)OC(=O)C1=CC(NOC(=O)CCCCCCC)=CC=C1O Chemical compound CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(=O)OC(=O)C1=CC(NC(=O)C2=C(O)C=CC(N)=C2)=CC=C1O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC(=O)OC(=O)C1=CC(NOC(=O)CCCCCCC)=CC=C1O SUJNDJFCLSMIIR-ABLNXSRISA-N 0.000 description 1
- AKXKFLWSJZVPRB-SRTJZQPYSA-N CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)CC1=CC=C(O)C(C(=O)O)=C1.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)Cl.NC1=CC(C(=O)O)=C(O)C=C1 Chemical compound CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)CC1=CC=C(O)C(C(=O)O)=C1.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)Cl.NC1=CC(C(=O)O)=C(O)C=C1 AKXKFLWSJZVPRB-SRTJZQPYSA-N 0.000 description 1
- CJAFQNPIGFXGDD-QZBAVZGHSA-N CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)Cl.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NC1=CC=C(O)C(C(=O)O)=C1.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NC1=CC=C(O)C(C(=O)OC(C)OC(=O)CCCCCCC)=C1.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(C)=O.CC=O.CCCCCCCC(=O)Cl.CCCCCCCC(=O)O.CCCCCCCC(=O)OC(C)I.NC1=CC(C(=O)O)=C(O)C=C1 Chemical compound CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)Cl.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NC1=CC=C(O)C(C(=O)O)=C1.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NC1=CC=C(O)C(C(=O)OC(C)OC(=O)CCCCCCC)=C1.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(C)=O.CC=O.CCCCCCCC(=O)Cl.CCCCCCCC(=O)O.CCCCCCCC(=O)OC(C)I.NC1=CC(C(=O)O)=C(O)C=C1 CJAFQNPIGFXGDD-QZBAVZGHSA-N 0.000 description 1
- CKJAMNDMPJQOAJ-GXEFYHESSA-N CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)Cl.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O Chemical compound CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)Cl.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O CKJAMNDMPJQOAJ-GXEFYHESSA-N 0.000 description 1
- OLNXJJQORYAMQF-FXCLNORQSA-N CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NC1=CC=C(O)C(C(=O)O)=C1.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NC1=CC=C(O)C(C(=O)OC(C)OC(=O)CCCCCCC)=C1.CCCCCCCC(=O)OC(C)I Chemical compound CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NC1=CC=C(O)C(C(=O)O)=C1.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)NC1=CC=C(O)C(C(=O)OC(C)OC(=O)CCCCCCC)=C1.CCCCCCCC(=O)OC(C)I OLNXJJQORYAMQF-FXCLNORQSA-N 0.000 description 1
- ZYIVZQNIPDJAKK-ZLQFEEABSA-N CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=C(O)C=CC(CC(=O)CCCCCCC)=C1.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=C(O)C=CC(N)=C1.CCCCCCCC(=O)O.NC1=CC(C(=O)O)=C(O)C=C1.NC1=CC(C(=O)O)=C(O)C=C1.O=C(O)C1=C(Cl)C=CC([N+](=O)[O-])=C1.O=C(O)C1=C(O)C=CC([N+](=O)[O-])=C1.O=S(Cl)Cl Chemical compound CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=C(O)C=CC(CC(=O)CCCCCCC)=C1.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=C(O)C=CC(N)=C1.CCCCCCCC(=O)O.NC1=CC(C(=O)O)=C(O)C=C1.NC1=CC(C(=O)O)=C(O)C=C1.O=C(O)C1=C(Cl)C=CC([N+](=O)[O-])=C1.O=C(O)C1=C(O)C=CC([N+](=O)[O-])=C1.O=S(Cl)Cl ZYIVZQNIPDJAKK-ZLQFEEABSA-N 0.000 description 1
- NIEUPNWHCLPNOS-SRTJZQPYSA-N CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=C(O)C=CC(N)=C1.NC1=CC(C(=O)Cl)=C(O)C=C1 Chemical compound CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=C(O)C=CC(N)=C1.NC1=CC(C(=O)Cl)=C(O)C=C1 NIEUPNWHCLPNOS-SRTJZQPYSA-N 0.000 description 1
- ZWZOGGOXJUVHIP-SRTJZQPYSA-N CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(N)C=C1O.NC1=CC(O)=C(ClC=O)C=C1 Chemical compound CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(N)C=C1O.NC1=CC(O)=C(ClC=O)C=C1 ZWZOGGOXJUVHIP-SRTJZQPYSA-N 0.000 description 1
- BPGLDRHKYAKXGI-YLIGDYLKSA-N CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(C)=O Chemical compound CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(C)=O BPGLDRHKYAKXGI-YLIGDYLKSA-N 0.000 description 1
- JRTMCOWDIMUZMT-LWIFVWKQSA-N CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=C(O)C=CC(CC(=O)CCCCCCC)=C1.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=C(O)C=CC(N)=C1.CCCCCCCC(=O)O Chemical compound CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=C(O)C=CC(CC(=O)CCCCCCC)=C1.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=C(O)C=CC(N)=C1.CCCCCCCC(=O)O JRTMCOWDIMUZMT-LWIFVWKQSA-N 0.000 description 1
- ZVAPPLBVWCXEGY-YLIGDYLKSA-N CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(N)C=C1O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(N)C=C1OC Chemical compound CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(N)C=C1O.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(N)C=C1OC ZVAPPLBVWCXEGY-YLIGDYLKSA-N 0.000 description 1
- VPKWKOIRRBZMJD-WHYDJOPQSA-N CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(N)C=C1OC.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(NC)C=C1OC.CCCCCCCC(=O)OC(=O)C1=C/C(=N/C)C=CC1=O Chemical compound CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(N)C=C1OC.CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC(=O)C1=CC=C(NC)C=C1OC.CCCCCCCC(=O)OC(=O)C1=C/C(=N/C)C=CC1=O VPKWKOIRRBZMJD-WHYDJOPQSA-N 0.000 description 1
- AVQGVUYPKFARNZ-UHFFFAOYSA-N CC=O.CCCCCCCC(=O)Cl.CCCCCCCC(=O)O.CCCCCCCC(=O)OC(C)I Chemical compound CC=O.CCCCCCCC(=O)Cl.CCCCCCCC(=O)O.CCCCCCCC(=O)OC(C)I AVQGVUYPKFARNZ-UHFFFAOYSA-N 0.000 description 1
- LYHUXAHUXHLREU-UHFFFAOYSA-N CCCCCCCC(=O)O.CCCCCCCC(=O)OC(=O)C1=CC=CC=C1O.O=C(Cl)C1=CC=CC=C1O Chemical compound CCCCCCCC(=O)O.CCCCCCCC(=O)OC(=O)C1=CC=CC=C1O.O=C(Cl)C1=CC=CC=C1O LYHUXAHUXHLREU-UHFFFAOYSA-N 0.000 description 1
- 235000013912 Ceratonia siliqua Nutrition 0.000 description 1
- 240000008886 Ceratonia siliqua Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- USXDFAGDIOXNML-UHFFFAOYSA-N Fulminate Chemical compound [O-][N+]#[C-] USXDFAGDIOXNML-UHFFFAOYSA-N 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- NUGPIZCTELGDOS-QHCPKHFHSA-N N-[(1S)-3-[4-(3-methyl-5-propan-2-yl-1,2,4-triazol-4-yl)piperidin-1-yl]-1-pyridin-3-ylpropyl]cyclopentanecarboxamide Chemical compound C(C)(C)C1=NN=C(N1C1CCN(CC1)CC[C@@H](C=1C=NC=CC=1)NC(=O)C1CCCC1)C NUGPIZCTELGDOS-QHCPKHFHSA-N 0.000 description 1
- JLPAQPUCXCLWOR-UHFFFAOYSA-N NC1=CC(C(=O)Cl)=C(O)C=C1.NC1=CC(C(=O)O)=C(O)C=C1.O=S(Cl)Cl Chemical compound NC1=CC(C(=O)Cl)=C(O)C=C1.NC1=CC(C(=O)O)=C(O)C=C1.O=S(Cl)Cl JLPAQPUCXCLWOR-UHFFFAOYSA-N 0.000 description 1
- PENHNDWKAURMMG-UHFFFAOYSA-N NC1=CC(C(=O)O)=C(O)C=C1.O=C(O)C1=C(O)C=CC([N+](=O)[O-])=C1 Chemical compound NC1=CC(C(=O)O)=C(O)C=C1.O=C(O)C1=C(O)C=CC([N+](=O)[O-])=C1 PENHNDWKAURMMG-UHFFFAOYSA-N 0.000 description 1
- ICBJMIMBLKKRFR-UHFFFAOYSA-N NC1=CC(O)=C(ClC=O)C=C1.NC1=CC(O)=C(OC=O)C=C1.O=S(Cl)Cl Chemical compound NC1=CC(O)=C(ClC=O)C=C1.NC1=CC(O)=C(OC=O)C=C1.O=S(Cl)Cl ICBJMIMBLKKRFR-UHFFFAOYSA-N 0.000 description 1
- 239000007832 Na2SO4 Substances 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- IUQBIDBPFYUNNO-UHFFFAOYSA-N O=C(Cl)C1=CC=CC=C1O.O=C(O)C1=CC=CC=C1O.O=S(Cl)Cl Chemical compound O=C(Cl)C1=CC=CC=C1O.O=C(O)C1=CC=CC=C1O.O=S(Cl)Cl IUQBIDBPFYUNNO-UHFFFAOYSA-N 0.000 description 1
- LZQDSCVOISCQBK-UHFFFAOYSA-N O=C(O)C1=C(Cl)C=CC([N+](=O)[O-])=C1.O=C(O)C1=C(O)C=CC([N+](=O)[O-])=C1 Chemical compound O=C(O)C1=C(Cl)C=CC([N+](=O)[O-])=C1.O=C(O)C1=C(O)C=CC([N+](=O)[O-])=C1 LZQDSCVOISCQBK-UHFFFAOYSA-N 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 208000023146 Pre-existing disease Diseases 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 206010036783 Proctitis ulcerative Diseases 0.000 description 1
- 239000007868 Raney catalyst Substances 0.000 description 1
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
- 229910000564 Raney nickel Inorganic materials 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038063 Rectal haemorrhage Diseases 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 239000004783 Serene Substances 0.000 description 1
- 244000000231 Sesamum indicum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 239000004163 Spermaceti wax Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 208000033809 Suppuration Diseases 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000012670 alkaline solution Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 229940092738 beeswax Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 208000027503 bloody stool Diseases 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000004204 candelilla wax Substances 0.000 description 1
- 235000013868 candelilla wax Nutrition 0.000 description 1
- 229940073532 candelilla wax Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000021466 carotenoid Nutrition 0.000 description 1
- 150000001747 carotenoids Chemical class 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 229960000913 crospovidone Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 125000000664 diazo group Chemical group [N-]=[N+]=[*] 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
- 208000014793 distal colitis Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000002706 dry binder Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000005370 electroosmosis Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 206010015037 epilepsy Diseases 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- SSQPWTVBQMWLSZ-AAQCHOMXSA-N ethyl (5Z,8Z,11Z,14Z,17Z)-icosapentaenoate Chemical compound CCOC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CC SSQPWTVBQMWLSZ-AAQCHOMXSA-N 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 208000018685 gastrointestinal system disease Diseases 0.000 description 1
- 235000010492 gellan gum Nutrition 0.000 description 1
- 239000000216 gellan gum Substances 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 229940049654 glyceryl behenate Drugs 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 229940074050 glyceryl myristate Drugs 0.000 description 1
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 1
- 229940046813 glyceryl palmitostearate Drugs 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- IUJAMGNYPWYUPM-UHFFFAOYSA-N hentriacontane Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCC IUJAMGNYPWYUPM-UHFFFAOYSA-N 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229920001519 homopolymer Polymers 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000010514 hydrogenated cottonseed oil Substances 0.000 description 1
- 235000019866 hydrogenated palm kernel oil Nutrition 0.000 description 1
- 239000008173 hydrogenated soybean oil Substances 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 208000016245 inborn errors of metabolism Diseases 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 208000015978 inherited metabolic disease Diseases 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000010030 laminating Methods 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- 150000002605 large molecules Chemical class 0.000 description 1
- 125000000400 lauroyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 230000008338 local blood flow Effects 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 239000000391 magnesium silicate Substances 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 229940099273 magnesium trisilicate Drugs 0.000 description 1
- 229910000386 magnesium trisilicate Inorganic materials 0.000 description 1
- 235000019793 magnesium trisilicate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 150000002734 metacrylic acid derivatives Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 239000004200 microcrystalline wax Substances 0.000 description 1
- 235000019808 microcrystalline wax Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008789 oxidative DNA damage Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000002638 palliative care Methods 0.000 description 1
- 208000014965 pancolitis Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 229960000292 pectin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001610 polycaprolactone Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920002635 polyurethane Polymers 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- DCBSHORRWZKAKO-UHFFFAOYSA-N rac-1-monomyristoylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OCC(O)CO DCBSHORRWZKAKO-UHFFFAOYSA-N 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229940100618 rectal suppository Drugs 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001846 repelling effect Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000011369 resultant mixture Substances 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N serine Chemical compound OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000012176 shellac wax Substances 0.000 description 1
- 231100000245 skin permeability Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 229940001474 sodium thiosulfate Drugs 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 235000019385 spermaceti wax Nutrition 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 125000003696 stearoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 229920006132 styrene block copolymer Polymers 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 235000016804 zinc Nutrition 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
- QUEDXNHFTDJVIY-UHFFFAOYSA-N γ-tocopherol Chemical class OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 QUEDXNHFTDJVIY-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
- A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
- A61K31/245—Amino benzoic acid types, e.g. procaine, novocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/606—Salicylic acid; Derivatives thereof having amino groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/54—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
- C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/70—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/72—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms
- C07C235/74—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups and doubly-bound oxygen atoms bound to the same carbon skeleton with the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of a saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C243/00—Compounds containing chains of nitrogen atoms singly-bound to each other, e.g. hydrazines, triazanes
- C07C243/10—Hydrazines
- C07C243/22—Hydrazines having nitrogen atoms of hydrazine groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
- C07C251/72—Hydrazones
- C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
Abstract
Description
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/834,411 US9333187B1 (en) | 2013-05-15 | 2015-08-24 | Compositions and methods for the treatment of inflammatory bowel disease |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14/533,111 US9498461B2 (en) | 2012-05-23 | 2013-05-15 | Compositions and methods for the treatment of inflammatory bowel disease |
US14/834,411 US9333187B1 (en) | 2013-05-15 | 2015-08-24 | Compositions and methods for the treatment of inflammatory bowel disease |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14533111 Continuation | 2014-11-05 |
Publications (2)
Publication Number | Publication Date |
---|---|
US20160120839A1 US20160120839A1 (en) | 2016-05-05 |
US9333187B1 true US9333187B1 (en) | 2016-05-10 |
Family
ID=86270947
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/834,411 Active US9333187B1 (en) | 2013-05-15 | 2015-08-24 | Compositions and methods for the treatment of inflammatory bowel disease |
Country Status (1)
Country | Link |
---|---|
US (1) | US9333187B1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2751770C2 (en) | 2016-08-11 | 2021-07-16 | Селликс Био Прайвет Лимитед | Compositions and methods of treatment of irritable bowel syndrome |
Citations (146)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2807644A (en) | 1954-08-20 | 1957-09-24 | Parke Davis & Co | Pantethine inhibitors |
GB1014020A (en) | 1963-08-20 | 1965-12-22 | Merck Ag E | Lipoic acid derivatives and their preparation |
GB1356470A (en) | 1971-06-02 | 1974-06-12 | Seperic | Ortho-disubstituted aryl-guanidines process for their preparation and applications thereof |
US4011342A (en) | 1971-06-02 | 1977-03-08 | Seperic | Method and composition for the treatment of hypertension with ortho-disubstituted arylguanidines |
AU514991B2 (en) | 1976-05-26 | 1981-03-12 | Commonwealth Of Australia, The | Pharmaceutical compositions containing antiinflammatory analgesic compounds |
JPS5677259A (en) | 1979-11-29 | 1981-06-25 | Nippon Chemiphar Co Ltd | N-pyridoxyl 5,8,11,14,17-eicosapentaenoic acid amide, and its preparation |
US4404366A (en) | 1980-05-06 | 1983-09-13 | Miles Laboratories, Inc. | Beta-galactosyl-umbelliferone-labeled hapten conjugates |
GB2116541A (en) | 1982-03-10 | 1983-09-28 | Ausonia Farma Srl | 2-phenyl-propionic acid ester derivative |
US4412992A (en) | 1980-07-21 | 1983-11-01 | Biorex Laboratories Limited | 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith |
US4440763A (en) | 1981-03-18 | 1984-04-03 | Block Drug Company, Inc. | Use of 4-aminosalicyclic acid as an anti-inflammatory agent |
WO1985000599A1 (en) | 1983-08-01 | 1985-02-14 | A/S Apothekernes Laboratorium For Specialpraeparat | L-N-n-PROPYLPIPECOLIC ACID-2,6-XYLIDIDE AND METHOD FOR PREPARING THE SAME |
EP0141393A2 (en) | 1983-11-04 | 1985-05-15 | Abbott Laboratories | Phenobarbital and carbamazepine enzyme inhibitors |
JPS6089474A (en) | 1983-10-20 | 1985-05-20 | Toyo Pharma- Kk | Morphinan derivative, production thereof and antitumor agent containing said compound |
EP0150787A2 (en) | 1984-02-02 | 1985-08-07 | PULITZER ITALIANA S.p.A. | Compound having antibronchopneumopathic activity, process for its preparation and pharmaceutical compositions containing it |
US4550109A (en) | 1984-05-31 | 1985-10-29 | The Board Of Regents, The University Of Texas System | Lipoidal biopterin compounds |
US4564628A (en) | 1983-01-03 | 1986-01-14 | Nelson Research & Development Co. | Substituted 2-aminotetralins |
US4778794A (en) | 1985-06-04 | 1988-10-18 | Suntory Limited | Pharmaceutical composition for the treatment of infantile autism |
US4873259A (en) | 1987-06-10 | 1989-10-10 | Abbott Laboratories | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds |
US4963590A (en) | 1986-11-28 | 1990-10-16 | Orion-Yhtyma Oy | Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same |
EP0421441A2 (en) | 1989-10-06 | 1991-04-10 | Fujirebio Inc. | Pantothenic acid derivatives |
US5013727A (en) | 1980-03-20 | 1991-05-07 | Farmaceutisk Laboratorium Ferring A/S | Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration |
WO1991014430A1 (en) | 1990-03-19 | 1991-10-03 | Research Corporation Technologies, Inc. | Topically active ocular thiadiazole sulfonamide carbonic anhydrase inhibitors |
WO1991018865A1 (en) | 1990-06-06 | 1991-12-12 | Yason S.R.L. | Antitussive and mucus regulating agent, a process for the preparation thereof and pharmaceutical compositions containing it |
US5102870A (en) | 1989-04-14 | 1992-04-07 | Schering Ag | Treatment and prevention of oral mucositis with growth factors |
US5104887A (en) | 1983-02-04 | 1992-04-14 | University Of Iowa Research Foundation | Topical ophthalmic imino substituted 2-imino-3-methyl-delta4-1,3,4-thiadiazoline-5-sulfonamides carbonic anhydrase inhibitors |
WO1994013298A1 (en) | 1992-12-16 | 1994-06-23 | Rhone-Poulenc Rorer S.A. | Application of carbamazepine and oxcarbazepine in the treatment of neurological lesions related to traumatic injuries |
WO1995022546A1 (en) | 1994-02-18 | 1995-08-24 | Cell Therapeutics, Inc. | Intracellular signalling mediators |
WO1995031464A1 (en) | 1994-05-18 | 1995-11-23 | Astra Aktiebolag | New agonist compounds |
FR2722199A1 (en) | 1994-07-11 | 1996-01-12 | Universite De Picardie Jules Verne Etabliss Public A Caract Scient Et Cult | New valproic acid ester(s) esp. of saccharide cpds. |
US5719168A (en) | 1993-06-30 | 1998-02-17 | Laboratoire L. Lafon | Acetamide derivatives and their use as feeding behaviour modifiers |
WO1998022433A1 (en) | 1996-11-22 | 1998-05-28 | Elan Pharmaceuticals, Inc. | N-(ARYL/HETEROARYL/ALKYLACETYL) AMINO ACID AMIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS |
WO1998052556A1 (en) | 1997-05-20 | 1998-11-26 | Scotia Holdings Plc | Glucosamine fatty acid compositions and their use |
CN1224610A (en) | 1998-01-02 | 1999-08-04 | 麦克尼尔-Ppc公司 | Ibuprofen compositions |
EP0934928A1 (en) | 1996-08-28 | 1999-08-11 | Sankyo Company Limited | Cyclic amine derivatives |
WO2000041693A2 (en) | 1999-01-11 | 2000-07-20 | The Procter & Gamble Company | Compositions having improved delivery of actives |
WO2000059851A1 (en) | 1999-04-06 | 2000-10-12 | Sepracor Inc. | Derivatives of venlafaxine and methods of preparing and using the same |
US6156777A (en) | 1994-12-15 | 2000-12-05 | Pharmacia & Upjohn Company | Use of pramipexole as a neuroprotective agent |
EP1063230A1 (en) | 1998-02-27 | 2000-12-27 | Sankyo Company Limited | Cyclic amino compounds |
WO2001022967A1 (en) | 1999-09-29 | 2001-04-05 | The Procter & Gamble Company | Compositions having improved stability |
CN1300213A (en) | 1998-05-15 | 2001-06-20 | 沃尼尔·朗伯公司 | Gamma-contained aminobutyric acid derivatives solid compositions and preparation process thereof |
WO2002000167A2 (en) | 2000-06-23 | 2002-01-03 | Medinox, Inc. | Modified forms of pharmacologically active agents and uses therefor |
US20020049155A1 (en) | 2000-05-31 | 2002-04-25 | Hogenkamp Henricus P.C. | Cobalamin compounds useful as cardiovascular agents and as imaging agents |
WO2002034713A1 (en) | 2000-10-24 | 2002-05-02 | Ajinomoto Co.,Inc. | Process for producing b-form nateglinide crystal |
US6414008B1 (en) | 1997-04-29 | 2002-07-02 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions |
WO2002062332A1 (en) | 2001-01-26 | 2002-08-15 | Neu Ingo S | Pharmaceutical composition for treating multiple sclerosis |
WO2002087512A2 (en) | 2001-05-02 | 2002-11-07 | Euro-Celtique, S.A. | Once-a-day oxycodone formulations |
WO2003018004A2 (en) | 2001-08-29 | 2003-03-06 | Endo Pharmaceuticals, Inc. | Analgetic pyrroline derivatives |
WO2003030877A1 (en) | 2001-10-10 | 2003-04-17 | The Procter & Gamble Company | Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer |
US6602915B2 (en) | 2000-07-27 | 2003-08-05 | Rutgers, The State University Of New Jersey | Therapeutic azo-compounds for drug delivery |
US6613802B1 (en) | 1999-06-04 | 2003-09-02 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
WO2003087038A1 (en) | 2002-04-15 | 2003-10-23 | Novartis Ag | Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine |
WO2003086391A1 (en) | 2002-04-16 | 2003-10-23 | Fujisawa Pharmaceutical Co., Ltd. | New use |
WO2003097656A2 (en) | 2002-05-13 | 2003-11-27 | Ortho-Mcneil Pharmaceutical, Inc. | Novel substituted sulfamate anticonvulsant derivatives |
US20040010038A1 (en) | 2002-02-27 | 2004-01-15 | Eran Blaugrund | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors |
WO2004031155A1 (en) | 2002-10-07 | 2004-04-15 | Novartis Ag | ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF |
WO2004052841A1 (en) | 2002-12-06 | 2004-06-24 | Xenoport, Inc. | Carbidopa prodrugs and uses thereof |
WO2004075886A1 (en) | 2003-02-14 | 2004-09-10 | Pierre Fabre Medicament | Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament |
WO2004078769A1 (en) | 2003-03-04 | 2004-09-16 | Ortho-Mcneil Pharmaceutical Inc. | Process for the preparation of anticonvulsant derivatives of topiramate |
WO2004082402A1 (en) | 2003-03-18 | 2004-09-30 | Novartis Ag | Compositions comprising fatty acids and amino acids |
US20050014799A1 (en) | 2003-06-20 | 2005-01-20 | Biostratum, Inc. | Pyridoxamine for the treatment of diabetic kidney disease |
US20050106248A1 (en) | 2003-11-17 | 2005-05-19 | Manesh Dixit | Extended release venlafaxine formulation |
WO2005046575A2 (en) | 2003-07-29 | 2005-05-26 | Signature R & D Holdings, Lcc | Amino acid prodrugs |
US20050208129A1 (en) | 2001-07-23 | 2005-09-22 | Bioalliance Pharma | Prolonged release bioadhesive therapeutic systems |
CN1672678A (en) | 2004-05-03 | 2005-09-28 | 深圳微芯生物科技有限责任公司 | Separation and extraction of natural active long-chain fatty acid component for preventing and treating prostatosis and the prepn and application of its medicine prepn |
US20050244486A1 (en) | 2004-04-29 | 2005-11-03 | Caldwell Larry J | Topical methadone compositions and methods for using the same |
WO2005116086A2 (en) | 2004-04-07 | 2005-12-08 | The University Of Georgia Research Foundation, Inc. | Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods |
CN1706813A (en) | 2004-06-09 | 2005-12-14 | 中国人民解放军军事医学科学院放射医学研究所 | Medicine precursor containing long chain fatty acyl group substituted venlafaxine and its prepn and use |
US20060057644A1 (en) | 2002-12-19 | 2006-03-16 | Kelly Jeffery W | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
CN1248690C (en) | 2004-03-25 | 2006-04-05 | 华中师范大学 | Oral preparation containing ranolazine hydrochloride for treating cardiovascular disease |
WO2006075123A1 (en) | 2005-01-14 | 2006-07-20 | Camurus Ab | Topical bioadhesive formulations |
EP1695962A1 (en) | 2003-11-28 | 2006-08-30 | Sankyo Company, Limited | Cyclic amine derivative having heteroaryl ring |
WO2006096996A1 (en) | 2005-03-18 | 2006-09-21 | Ripped Formulations Ltd. | Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition |
WO2006120176A2 (en) | 2005-05-11 | 2006-11-16 | Nycomed Gmbh | Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative |
WO2006125293A1 (en) | 2005-05-27 | 2006-11-30 | Antibe Therapeutics Inc. | Derivatives of 4- or 5-aminosalicylic acid |
US20060270635A1 (en) | 2005-05-27 | 2006-11-30 | Wallace John L | Derivatives of 4- or 5-aminosalicylic acid |
CN1897935A (en) | 2003-12-24 | 2007-01-17 | 施瓦茨制药有限公司 | Use of rotigotine for treatment or prevention of dopaminergic neurone loss |
WO2007086493A1 (en) | 2006-01-27 | 2007-08-02 | Asahi Kasei Pharma Corporation | Medicine for transnasal administration |
CN101023056A (en) | 2004-06-04 | 2007-08-22 | 克塞诺波特公司 | Levodopa prodrugs, and compositions and uses thereof |
WO2007121188A2 (en) | 2006-04-10 | 2007-10-25 | Knopp Neurosciences, Inc. | Compositions and methods of using r(+) pramipexole |
EP1870395A1 (en) | 2006-06-19 | 2007-12-26 | KRKA, D.D., Novo Mesto | Process for preparation of o-desmethylvenlafaxine and its analogue |
US20080020996A1 (en) | 2006-07-24 | 2008-01-24 | Chandra Ulagaraj Singh | Esters of capsaicin for treating pain |
EP1889835A1 (en) | 2005-05-27 | 2008-02-20 | Daiichi Sankyo Company, Limited | Cyclic amine derivative having substituted alkyl group |
US20080058362A1 (en) | 2006-08-31 | 2008-03-06 | Singh Chandra U | Novel pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
WO2008030567A2 (en) | 2006-09-08 | 2008-03-13 | Wyeth | Dry powder compound formulations and uses thereof |
CN101186583A (en) | 2007-12-20 | 2008-05-28 | 吉林大学 | Methyl 2-(2-(2,6-dichlorophenylamino)phenyl)acetate and its synthesizing method and application |
CN101202326A (en) | 2006-12-14 | 2008-06-18 | 财团法人工业技术研究院 | Phase-change storage apparatus and method of manufacture |
WO2008074033A1 (en) | 2006-12-14 | 2008-06-19 | Knopp Neurosciences, Inc. | Compositions and methods of using (r)-pramipexole |
CN101208326A (en) | 2005-05-13 | 2008-06-25 | 艾诺伊洛克有限公司 | Derivate von dihydroxyphenylalanin |
WO2008079404A2 (en) | 2006-12-22 | 2008-07-03 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
WO2008089008A2 (en) | 2007-01-12 | 2008-07-24 | Biomarin Pharmaceutical Inc. | Tetrahydrobiopterin prodrugs |
WO2008098960A1 (en) | 2007-02-13 | 2008-08-21 | Chemo Iberica, S. A. | Process for preparing entacapone substantially free of z-isomer, synthesis intermediates thereof and a new crystalline form |
US20080227985A1 (en) | 2007-03-14 | 2008-09-18 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazoles |
US20080262053A1 (en) | 2005-10-18 | 2008-10-23 | Juergen Reess | Use of Pramipexole for Treating Moderate to Severe Restless Legs Syndrome (Rls) |
WO2008137474A1 (en) | 2007-05-01 | 2008-11-13 | Concert Pharmaceuticals Inc. | Morphinan compounds |
EP1997493A1 (en) | 2007-05-28 | 2008-12-03 | Laboratorios del Dr. Esteve S.A. | Combination of a 5-HT7 receptor ligand and an opioid receptor ligand |
WO2009002297A1 (en) | 2007-06-22 | 2008-12-31 | Gluconova Llc | Halide-free glucosamine-acidic drug complexes |
US20090075942A1 (en) | 2007-09-13 | 2009-03-19 | Protia, Llc | Deuterium-enriched fosamprenavir |
CN101390854A (en) | 2007-09-21 | 2009-03-25 | 北京德众万全药物技术开发有限公司 | Medical composition containing riluzole |
WO2009056791A1 (en) | 2007-11-02 | 2009-05-07 | Pliva Hrvatska D.O.O. | Processes for preparing pharmaceutical compounds |
US20090118365A1 (en) | 2007-11-06 | 2009-05-07 | Xenoport, Inc | Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain |
CN100548300C (en) | 2002-04-04 | 2009-10-14 | Cv医药有限公司 | Ranolazine is in the application that is used for preparing treatment arrhythmia medicament |
CN101569618A (en) | 2008-04-30 | 2009-11-04 | 上海医药工业研究院 | Application of long-chain fatty acid derivative or plant extracts containing same in inhibiting the activity of aromatizing enzyme |
WO2010020969A1 (en) | 2008-08-22 | 2010-02-25 | Wockhardt Research Centre | An extended release pharmaceutical composition of entacapone or salts thereof |
WO2010031819A1 (en) | 2008-09-18 | 2010-03-25 | Bioalliance Pharma | Treating inflammation and inflammatory pain in mucosa using mucosal prolonged release bioadhesive therapeutic carriers. |
US20100081713A1 (en) | 2008-03-19 | 2010-04-01 | CombinatoRx, (Singapore) Pte. Ltd. | Compositions and methods for treating viral infections |
CN101717392A (en) | 2009-10-09 | 2010-06-02 | 苏州凯达生物医药技术有限公司 | Method for preparing rotigotine and derivative thereof |
CN101724934A (en) | 2009-11-10 | 2010-06-09 | 东华大学 | Medicinal fibre used for treating cutaneous inflammation and pain, preparation and application thereof |
US20100184730A1 (en) * | 2008-07-08 | 2010-07-22 | Vu Chi B | Fatty Acid Acylated Salicylates and Their Uses |
WO2010115252A1 (en) | 2009-04-06 | 2010-10-14 | Ems S.A. | PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-α MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES |
WO2010127099A2 (en) | 2009-04-29 | 2010-11-04 | Amarin Corporation Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
CN101921245A (en) | 2010-08-30 | 2010-12-22 | 中国人民解放军军事医学科学院卫生学环境医学研究所 | Sulfonamides compound for inhibiting carbonic anhydrase II and synthesis method and application thereof |
WO2010147666A1 (en) | 2009-06-19 | 2010-12-23 | Memorial Sloan-Kettering Cancer Center | Compounds useful as carbonic anhydrase modulators and uses thereof |
US20110021628A1 (en) | 2003-10-14 | 2011-01-27 | Xenoport, Inc. | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG |
WO2011017800A1 (en) | 2009-08-10 | 2011-02-17 | Bellus Health (International) Limited | Methods, compounds, and compositions for delivering 1,3-propan ed isulfonic acid |
EP2298777A2 (en) | 2008-06-09 | 2011-03-23 | Enzytech, Ltd. | Method for preparing clopidogrel and its derivatives |
CN102002053A (en) | 2009-09-02 | 2011-04-06 | 陕西合成药业有限公司 | Tetrahydro thienopyridine derivative for treating |
WO2011060945A2 (en) | 2009-11-20 | 2011-05-26 | Gp Pharm, S.A. | Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases |
CN102123763A (en) | 2008-08-19 | 2011-07-13 | 什诺波特有限公司 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
US20110172240A1 (en) | 2010-01-08 | 2011-07-14 | Milne Jill C | Fatty acid fumarate derivatives and their uses |
WO2011089216A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
CN102149673A (en) | 2008-07-08 | 2011-08-10 | 凯特贝希制药公司 | Fatty acid acetylated salicylates and their uses |
WO2011106688A1 (en) | 2010-02-26 | 2011-09-01 | Catabasis Pharmaceuticals, Inc. | Bis-fatty acid conjugates and their uses |
US20110300190A1 (en) | 2010-06-08 | 2011-12-08 | Krisani Biosciences (P) Ltd | Compound, composition and uses thereof |
RU2436772C2 (en) | 2010-01-28 | 2011-12-20 | Закрытое акционерное общество "НПК ЭХО" | 4[(4'-nicotinoylamino)butyroylamino]butanoic acid, exhibiting nootropic activity, and method of producing said compound |
US20110313176A1 (en) | 2008-12-26 | 2011-12-22 | Actavis Group Ptc Ehf | Processes for preparing highly pure rotigotine or a pharmaceutically acceptable salt thereof |
WO2012007352A1 (en) | 2010-07-12 | 2012-01-19 | Boehringer Ingelheim International Gmbh | Aqueous composition comprising bromhexine |
CN102336767A (en) | 2011-07-11 | 2012-02-01 | 华东理工大学 | Method for preparing high-purity chiral alpha-substituted-6,7-thiaindan[3,2-c]pyridine derivative |
US20120046272A1 (en) | 2010-08-23 | 2012-02-23 | Grunenthal Gmbh | Novel Therapeutic Compounds |
WO2012027543A1 (en) | 2010-08-25 | 2012-03-01 | Teva Pharmaceuticals Usa, Inc. | Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof |
WO2012055567A2 (en) | 2010-10-29 | 2012-05-03 | Algiax Pharmaceuticals Gmbh | Use of malononitrilamides in neuropathic pain |
EP2450039A1 (en) | 2010-11-08 | 2012-05-09 | PAION UK Ltd. | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
CN102633799A (en) | 2012-04-10 | 2012-08-15 | 凯莱英医药集团(天津)股份有限公司 | Method for synthesizing sapropterin dihydrochloride from racemate intermediate separation route |
WO2012115695A1 (en) | 2011-02-25 | 2012-08-30 | Catabasis Pharmaceuticals, Inc. | Bis-fatty acid conjugates and their uses |
WO2013008182A1 (en) | 2011-07-10 | 2013-01-17 | Mahesh Kandula | Prodrugs of gaba analogs |
WO2013017974A1 (en) | 2011-07-30 | 2013-02-07 | Mahesh Kandula | Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases |
WO2013024376A1 (en) | 2011-08-16 | 2013-02-21 | Mahesh Kandula | Compositions and methods for the treatment of atherothrombosis |
WO2013027150A1 (en) | 2011-08-21 | 2013-02-28 | Mahesh Kandula | Compositions and methods for the treatment of parkinson's disease |
WO2013167996A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
WO2013167988A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of cough |
WO2013168022A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treating atherothrombosis |
WO2013167993A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological degenerative disorders |
WO2013175377A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
JP5412340B2 (en) | 2010-03-19 | 2014-02-12 | 本田技研工業株式会社 | Vehicle viewing window |
CN102050815B (en) | 2009-11-06 | 2014-04-02 | 北京美倍他药物研究有限公司 | Dabigatran ester derivatives as prodrug |
US8952068B2 (en) | 2013-06-04 | 2015-02-10 | Mahesh Kandula | Compositions for the treatment of diabetes and pre-diabetes |
WO2014174425A3 (en) | 2013-04-24 | 2015-02-19 | Mahesh Kandula | Compositions and methods for the treatment of orthostasis and neurological diseases |
-
2015
- 2015-08-24 US US14/834,411 patent/US9333187B1/en active Active
Patent Citations (221)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2807644A (en) | 1954-08-20 | 1957-09-24 | Parke Davis & Co | Pantethine inhibitors |
GB1014020A (en) | 1963-08-20 | 1965-12-22 | Merck Ag E | Lipoic acid derivatives and their preparation |
GB1356470A (en) | 1971-06-02 | 1974-06-12 | Seperic | Ortho-disubstituted aryl-guanidines process for their preparation and applications thereof |
US4011342A (en) | 1971-06-02 | 1977-03-08 | Seperic | Method and composition for the treatment of hypertension with ortho-disubstituted arylguanidines |
AU514991B2 (en) | 1976-05-26 | 1981-03-12 | Commonwealth Of Australia, The | Pharmaceutical compositions containing antiinflammatory analgesic compounds |
JPS5677259A (en) | 1979-11-29 | 1981-06-25 | Nippon Chemiphar Co Ltd | N-pyridoxyl 5,8,11,14,17-eicosapentaenoic acid amide, and its preparation |
US5013727A (en) | 1980-03-20 | 1991-05-07 | Farmaceutisk Laboratorium Ferring A/S | Pharmaceutical composition and method for the treatment of colitis ulcerosa and Crohn's disease by oral administration |
US4404366A (en) | 1980-05-06 | 1983-09-13 | Miles Laboratories, Inc. | Beta-galactosyl-umbelliferone-labeled hapten conjugates |
US4412992A (en) | 1980-07-21 | 1983-11-01 | Biorex Laboratories Limited | 2-Hydroxy-5-phenylazobenzoic acid derivatives and method of treating ulcerative colitis therewith |
US4440763A (en) | 1981-03-18 | 1984-04-03 | Block Drug Company, Inc. | Use of 4-aminosalicyclic acid as an anti-inflammatory agent |
GB2116541A (en) | 1982-03-10 | 1983-09-28 | Ausonia Farma Srl | 2-phenyl-propionic acid ester derivative |
US4564628A (en) | 1983-01-03 | 1986-01-14 | Nelson Research & Development Co. | Substituted 2-aminotetralins |
US5104887A (en) | 1983-02-04 | 1992-04-14 | University Of Iowa Research Foundation | Topical ophthalmic imino substituted 2-imino-3-methyl-delta4-1,3,4-thiadiazoline-5-sulfonamides carbonic anhydrase inhibitors |
WO1985000599A1 (en) | 1983-08-01 | 1985-02-14 | A/S Apothekernes Laboratorium For Specialpraeparat | L-N-n-PROPYLPIPECOLIC ACID-2,6-XYLIDIDE AND METHOD FOR PREPARING THE SAME |
JPS6089474A (en) | 1983-10-20 | 1985-05-20 | Toyo Pharma- Kk | Morphinan derivative, production thereof and antitumor agent containing said compound |
EP0141393A2 (en) | 1983-11-04 | 1985-05-15 | Abbott Laboratories | Phenobarbital and carbamazepine enzyme inhibitors |
EP0150787A2 (en) | 1984-02-02 | 1985-08-07 | PULITZER ITALIANA S.p.A. | Compound having antibronchopneumopathic activity, process for its preparation and pharmaceutical compositions containing it |
US4550109A (en) | 1984-05-31 | 1985-10-29 | The Board Of Regents, The University Of Texas System | Lipoidal biopterin compounds |
US4778794A (en) | 1985-06-04 | 1988-10-18 | Suntory Limited | Pharmaceutical composition for the treatment of infantile autism |
US4920122A (en) | 1985-06-04 | 1990-04-24 | Suntory Limited | Pharmaceutical composition and method for the treatment of infantile autism |
US4963590A (en) | 1986-11-28 | 1990-10-16 | Orion-Yhtyma Oy | Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same |
US4873259A (en) | 1987-06-10 | 1989-10-10 | Abbott Laboratories | Indole, benzofuran, benzothiophene containing lipoxygenase inhibiting compounds |
US5102870A (en) | 1989-04-14 | 1992-04-07 | Schering Ag | Treatment and prevention of oral mucositis with growth factors |
EP0421441A2 (en) | 1989-10-06 | 1991-04-10 | Fujirebio Inc. | Pantothenic acid derivatives |
US5120738A (en) | 1989-10-06 | 1992-06-09 | Fujirebio Inc. | Pantothenic acid derivatives |
WO1991014430A1 (en) | 1990-03-19 | 1991-10-03 | Research Corporation Technologies, Inc. | Topically active ocular thiadiazole sulfonamide carbonic anhydrase inhibitors |
US5242937A (en) | 1990-03-19 | 1993-09-07 | Research Corporation Technologies, Inc. | Topically active ocular thiadiazole sulfonamide carbonic anhydrase inhibitors |
US5352703A (en) | 1990-06-06 | 1994-10-04 | Mediolanum Farmaceutici S.P.A. | Antitussive and mucus regulating agent, a process for the preparation thereof and pharmaceutical compositions containing it |
WO1991018865A1 (en) | 1990-06-06 | 1991-12-12 | Yason S.R.L. | Antitussive and mucus regulating agent, a process for the preparation thereof and pharmaceutical compositions containing it |
WO1993005029A1 (en) | 1991-08-28 | 1993-03-18 | University Of Iowa Research Foundation | Topical ophthalmic imino substituted 2-imino-3-methyl-δ4-1,3,4-thiadiazoline-5-sulfonamides carbonic anhydrase inhibitors |
WO1994013298A1 (en) | 1992-12-16 | 1994-06-23 | Rhone-Poulenc Rorer S.A. | Application of carbamazepine and oxcarbazepine in the treatment of neurological lesions related to traumatic injuries |
US5830907A (en) | 1992-12-16 | 1998-11-03 | Rhone-Poulenc Rorer, S.A. | Application of riluzole in the treatment of neurological lesions associated with trauma |
US5719168A (en) | 1993-06-30 | 1998-02-17 | Laboratoire L. Lafon | Acetamide derivatives and their use as feeding behaviour modifiers |
WO1995022546A1 (en) | 1994-02-18 | 1995-08-24 | Cell Therapeutics, Inc. | Intracellular signalling mediators |
WO1995031464A1 (en) | 1994-05-18 | 1995-11-23 | Astra Aktiebolag | New agonist compounds |
US5886001A (en) | 1994-05-18 | 1999-03-23 | Astra Ab | Agonist compounds |
FR2722199A1 (en) | 1994-07-11 | 1996-01-12 | Universite De Picardie Jules Verne Etabliss Public A Caract Scient Et Cult | New valproic acid ester(s) esp. of saccharide cpds. |
US6156777A (en) | 1994-12-15 | 2000-12-05 | Pharmacia & Upjohn Company | Use of pramipexole as a neuroprotective agent |
EP0934928A1 (en) | 1996-08-28 | 1999-08-11 | Sankyo Company Limited | Cyclic amine derivatives |
WO1998022433A1 (en) | 1996-11-22 | 1998-05-28 | Elan Pharmaceuticals, Inc. | N-(ARYL/HETEROARYL/ALKYLACETYL) AMINO ACID AMIDES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND METHODS FOR INHIBITING β-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS BY USE OF SUCH COMPOUNDS |
US6414008B1 (en) | 1997-04-29 | 2002-07-02 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions |
WO1998052556A1 (en) | 1997-05-20 | 1998-11-26 | Scotia Holdings Plc | Glucosamine fatty acid compositions and their use |
CN1224610A (en) | 1998-01-02 | 1999-08-04 | 麦克尼尔-Ppc公司 | Ibuprofen compositions |
US8025897B2 (en) | 1998-01-02 | 2011-09-27 | Mcneil-Ppc, Inc. | Ibuprofen composition |
US20040048924A1 (en) | 1998-01-02 | 2004-03-11 | Bunick Frank J. | Ibuprofen composition |
EP1063230A1 (en) | 1998-02-27 | 2000-12-27 | Sankyo Company Limited | Cyclic amino compounds |
US6610708B1 (en) | 1998-02-27 | 2003-08-26 | Sankyo Company, Limited | Cyclic amino compounds |
CN1300213A (en) | 1998-05-15 | 2001-06-20 | 沃尼尔·朗伯公司 | Gamma-contained aminobutyric acid derivatives solid compositions and preparation process thereof |
WO2000041693A2 (en) | 1999-01-11 | 2000-07-20 | The Procter & Gamble Company | Compositions having improved delivery of actives |
US20030139437A1 (en) | 1999-01-11 | 2003-07-24 | Dobrozsi Douglas Joseph | Compositions having improved delivery of actives |
US20040106576A1 (en) | 1999-04-06 | 2004-06-03 | Sepracor Inc. | Derivatives of venlafaxine and methods of preparing and using the same |
US20080269166A2 (en) | 1999-04-06 | 2008-10-30 | Sepracor Inc. | Derivatives of venlafaxine and methods of preparing and using the same |
WO2000059851A1 (en) | 1999-04-06 | 2000-10-12 | Sepracor Inc. | Derivatives of venlafaxine and methods of preparing and using the same |
US20120302794A1 (en) | 1999-04-06 | 2012-11-29 | Jerussi Thomas P | Derivatives of venlafaxine and methods of preparing and using the same |
US20080132578A1 (en) | 1999-04-06 | 2008-06-05 | Sepracor Inc. | Dosage forms of O-desmethylvenlafaxine |
US6613802B1 (en) | 1999-06-04 | 2003-09-02 | Metabolex, Inc. | Use of (-) (3-trihalomethylphenoxy) (4-halophenyl) acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidemia and hyperuricemia |
WO2001022967A1 (en) | 1999-09-29 | 2001-04-05 | The Procter & Gamble Company | Compositions having improved stability |
US20020049155A1 (en) | 2000-05-31 | 2002-04-25 | Hogenkamp Henricus P.C. | Cobalamin compounds useful as cardiovascular agents and as imaging agents |
US20030220468A1 (en) | 2000-06-23 | 2003-11-27 | Medinox, Inc. | Modified forms of pharmacologically active agents and uses therefor |
WO2002000167A2 (en) | 2000-06-23 | 2002-01-03 | Medinox, Inc. | Modified forms of pharmacologically active agents and uses therefor |
US6602915B2 (en) | 2000-07-27 | 2003-08-05 | Rutgers, The State University Of New Jersey | Therapeutic azo-compounds for drug delivery |
US7544834B2 (en) | 2000-10-24 | 2009-06-09 | Ajinomoto Co., Inc. | Methods for producing nateglinide B-type crystals |
WO2002034713A1 (en) | 2000-10-24 | 2002-05-02 | Ajinomoto Co.,Inc. | Process for producing b-form nateglinide crystal |
WO2002062332A1 (en) | 2001-01-26 | 2002-08-15 | Neu Ingo S | Pharmaceutical composition for treating multiple sclerosis |
US20050020665A1 (en) | 2001-01-26 | 2005-01-27 | Ingo Neu | Pharmaceutical composition for treating multiple sclerosis |
WO2002087512A2 (en) | 2001-05-02 | 2002-11-07 | Euro-Celtique, S.A. | Once-a-day oxycodone formulations |
US20040170680A1 (en) | 2001-05-02 | 2004-09-02 | Benjamin Oshlack | Once-a-day oxycodone formulations |
US20050208129A1 (en) | 2001-07-23 | 2005-09-22 | Bioalliance Pharma | Prolonged release bioadhesive therapeutic systems |
WO2003018004A2 (en) | 2001-08-29 | 2003-03-06 | Endo Pharmaceuticals, Inc. | Analgetic pyrroline derivatives |
WO2003030877A1 (en) | 2001-10-10 | 2003-04-17 | The Procter & Gamble Company | Orally administered liquid compositions comprising guaifenesin and a polyoxyalkylene block copolymer |
US20090131535A1 (en) | 2002-02-27 | 2009-05-21 | Teva Pharmaceuticals Industries, Ltd. | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective mao inhibitors |
US20040010038A1 (en) | 2002-02-27 | 2004-01-15 | Eran Blaugrund | Propargylamino indan derivatives and propargylamino tetralin derivatives as brain-selective MAO inhibitors |
US20100004255A1 (en) | 2002-04-04 | 2010-01-07 | Luiz Belardinelli | Method of treating arrhythmias |
CN100548300C (en) | 2002-04-04 | 2009-10-14 | Cv医药有限公司 | Ranolazine is in the application that is used for preparing treatment arrhythmia medicament |
US20080319222A1 (en) | 2002-04-15 | 2008-12-25 | Sutton Paul A | Crystal forms of N- (trans-4-isopropylctyclohexylcarbonyl) -D-phenylalanine |
WO2003087038A1 (en) | 2002-04-15 | 2003-10-23 | Novartis Ag | Crystal forms of n-(trans-4-isopropylcyclohexylcarbonyl)-d-phenylalanine |
WO2003086391A1 (en) | 2002-04-16 | 2003-10-23 | Fujisawa Pharmaceutical Co., Ltd. | New use |
US20030232867A1 (en) | 2002-04-16 | 2003-12-18 | Masakazu Kobayashi | Use |
US20060058373A1 (en) | 2002-05-13 | 2006-03-16 | Ahmed Abdel-Magid | Novel substituted sulfamate anticonvulsant derivatives |
WO2003097656A2 (en) | 2002-05-13 | 2003-11-27 | Ortho-Mcneil Pharmaceutical, Inc. | Novel substituted sulfamate anticonvulsant derivatives |
WO2004031155A1 (en) | 2002-10-07 | 2004-04-15 | Novartis Ag | ENANTIOSELECTIVE PROCESS FOR THE PREPARATION OF BOTH ENANTIOMERS OF 10,11-DIHYDRO-10-HYDROXY-5H-DIBENZ [b,f]AZEPINE-5-CARBOXAMIDE AND NEW CRYSTAL FORMS THEREOF |
US20060142566A1 (en) | 2002-10-07 | 2006-06-29 | Christian Mathes | Enantioselective process for the preparation of both enantiomers of 10,11-dihydro-10-hydroxy-5h-dibenz[b,f]azepine-5-carboxamide and new crystal forms thereof |
WO2004052841A1 (en) | 2002-12-06 | 2004-06-24 | Xenoport, Inc. | Carbidopa prodrugs and uses thereof |
US7101912B2 (en) | 2002-12-06 | 2006-09-05 | Xenoport, Inc. | Carbidopa prodrugs and derivatives, and compositions and uses thereof |
CN100448852C (en) | 2002-12-19 | 2009-01-07 | 斯克里普斯研究学院 | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
US20140134753A1 (en) | 2002-12-19 | 2014-05-15 | The Scripps Research Institute | Methods for treating transthyretin amyloid diseases |
US20060057644A1 (en) | 2002-12-19 | 2006-03-16 | Kelly Jeffery W | Compositions and methods for stabilizing transthyretin and inhibiting transthyretin misfolding |
US20040259953A1 (en) | 2003-02-14 | 2004-12-23 | Jean Deregnaucourt | Use of the (1S,2R) enantiomer of milnacipran for the preparation of a drug |
US20060014837A1 (en) | 2003-02-14 | 2006-01-19 | Pierre Fabre Medicament | Use of the (1S, 2R) enantiomer of milnacipran for the preparation of a drug |
WO2004075886A1 (en) | 2003-02-14 | 2004-09-10 | Pierre Fabre Medicament | Use of the enantiomer (1s, 2r) of milnacipran for the preparation of a medicament |
WO2004078769A1 (en) | 2003-03-04 | 2004-09-16 | Ortho-Mcneil Pharmaceutical Inc. | Process for the preparation of anticonvulsant derivatives of topiramate |
US20040215004A1 (en) | 2003-03-04 | 2004-10-28 | Berkner Joachim Ernst | One step process for the preparation of anticonvulsant derivatives |
WO2004082402A1 (en) | 2003-03-18 | 2004-09-30 | Novartis Ag | Compositions comprising fatty acids and amino acids |
US20050014799A1 (en) | 2003-06-20 | 2005-01-20 | Biostratum, Inc. | Pyridoxamine for the treatment of diabetic kidney disease |
WO2005046575A2 (en) | 2003-07-29 | 2005-05-26 | Signature R & D Holdings, Lcc | Amino acid prodrugs |
US20140235710A1 (en) | 2003-10-14 | 2014-08-21 | Xenoport, Inc. | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG |
US20110313036A1 (en) | 2003-10-14 | 2011-12-22 | Xenoport, Inc. | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG |
US20110021628A1 (en) | 2003-10-14 | 2011-01-27 | Xenoport, Inc. | CRYSTALLINE FORM OF y-AMINOBUTYRIC ACID ANALOG |
US20050106248A1 (en) | 2003-11-17 | 2005-05-19 | Manesh Dixit | Extended release venlafaxine formulation |
US20110165234A1 (en) | 2003-11-17 | 2011-07-07 | Andrx Pharmaceuticals, Llc | Extended release venlafaxine formulation |
EP1695962A1 (en) | 2003-11-28 | 2006-08-30 | Sankyo Company, Limited | Cyclic amine derivative having heteroaryl ring |
US20060270706A1 (en) | 2003-11-28 | 2006-11-30 | Tomio Kimura | Cyclic amine derivative having heteroaryl ring |
CN1897935A (en) | 2003-12-24 | 2007-01-17 | 施瓦茨制药有限公司 | Use of rotigotine for treatment or prevention of dopaminergic neurone loss |
CN1248690C (en) | 2004-03-25 | 2006-04-05 | 华中师范大学 | Oral preparation containing ranolazine hydrochloride for treating cardiovascular disease |
WO2005116086A2 (en) | 2004-04-07 | 2005-12-08 | The University Of Georgia Research Foundation, Inc. | Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods |
US20120021046A1 (en) | 2004-04-07 | 2012-01-26 | Capomacchia Anthony C | Glucosamine and glucosamine/anti-inflammatory mutual prodrugs, compositions, and methods |
WO2005110381A1 (en) | 2004-04-29 | 2005-11-24 | Caldwell Galer, Inc. | Topical methadone compositions and methods for using the same |
US20050244486A1 (en) | 2004-04-29 | 2005-11-03 | Caldwell Larry J | Topical methadone compositions and methods for using the same |
CN1672678A (en) | 2004-05-03 | 2005-09-28 | 深圳微芯生物科技有限责任公司 | Separation and extraction of natural active long-chain fatty acid component for preventing and treating prostatosis and the prepn and application of its medicine prepn |
CN101023056A (en) | 2004-06-04 | 2007-08-22 | 克塞诺波特公司 | Levodopa prodrugs, and compositions and uses thereof |
CN1706813A (en) | 2004-06-09 | 2005-12-14 | 中国人民解放军军事医学科学院放射医学研究所 | Medicine precursor containing long chain fatty acyl group substituted venlafaxine and its prepn and use |
WO2006075123A1 (en) | 2005-01-14 | 2006-07-20 | Camurus Ab | Topical bioadhesive formulations |
WO2006096996A1 (en) | 2005-03-18 | 2006-09-21 | Ripped Formulations Ltd. | Compositions and methods for increasing metabolism, thermogenesis and/or muscular definition |
WO2006120176A2 (en) | 2005-05-11 | 2006-11-16 | Nycomed Gmbh | Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative |
US20080221111A1 (en) | 2005-05-11 | 2008-09-11 | Nycomed Gmbh | Combination of a Pd4 Inhibitor and a Tetrahydrobiopterin Derivative |
CN101208326A (en) | 2005-05-13 | 2008-06-25 | 艾诺伊洛克有限公司 | Derivate von dihydroxyphenylalanin |
US7910568B2 (en) | 2005-05-27 | 2011-03-22 | Antibe Therapeutics Inc. | Derivatives of 4- or 5-aminosalicylic acid |
EP1889835A1 (en) | 2005-05-27 | 2008-02-20 | Daiichi Sankyo Company, Limited | Cyclic amine derivative having substituted alkyl group |
US20060270635A1 (en) | 2005-05-27 | 2006-11-30 | Wallace John L | Derivatives of 4- or 5-aminosalicylic acid |
WO2006125293A1 (en) | 2005-05-27 | 2006-11-30 | Antibe Therapeutics Inc. | Derivatives of 4- or 5-aminosalicylic acid |
US20080207564A1 (en) | 2005-05-27 | 2008-08-28 | Antibe Therapeutics Inc. | Derivaitves of 4-Or 5-Aminosalicylic Acid |
US20080262053A1 (en) | 2005-10-18 | 2008-10-23 | Juergen Reess | Use of Pramipexole for Treating Moderate to Severe Restless Legs Syndrome (Rls) |
WO2007086493A1 (en) | 2006-01-27 | 2007-08-02 | Asahi Kasei Pharma Corporation | Medicine for transnasal administration |
US20070259930A1 (en) | 2006-04-10 | 2007-11-08 | Knopp Neurosciences, Inc. | Compositions and methods of using r(+) pramipexole |
WO2007121188A2 (en) | 2006-04-10 | 2007-10-25 | Knopp Neurosciences, Inc. | Compositions and methods of using r(+) pramipexole |
EP1870395A1 (en) | 2006-06-19 | 2007-12-26 | KRKA, D.D., Novo Mesto | Process for preparation of o-desmethylvenlafaxine and its analogue |
US20110218180A1 (en) | 2006-07-24 | 2011-09-08 | Trinity Laboratiories, Inc. | Esters of Capsaicin for Treating Pain |
US20080020996A1 (en) | 2006-07-24 | 2008-01-24 | Chandra Ulagaraj Singh | Esters of capsaicin for treating pain |
US20080058362A1 (en) | 2006-08-31 | 2008-03-06 | Singh Chandra U | Novel pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
US7645767B2 (en) | 2006-08-31 | 2010-01-12 | Trinity Laboratories, Inc. | Pharmaceutical compositions for treating chronic pain and pain associated with neuropathy |
US20140228389A1 (en) | 2006-09-08 | 2014-08-14 | Wyeth, Llc | Dry powder compound formulations and uses thereof |
US20080064743A1 (en) | 2006-09-08 | 2008-03-13 | Wyeth | Dry powder compound formulations and uses thereof |
WO2008030567A2 (en) | 2006-09-08 | 2008-03-13 | Wyeth | Dry powder compound formulations and uses thereof |
CN101202326A (en) | 2006-12-14 | 2008-06-18 | 财团法人工业技术研究院 | Phase-change storage apparatus and method of manufacture |
WO2008074033A1 (en) | 2006-12-14 | 2008-06-19 | Knopp Neurosciences, Inc. | Compositions and methods of using (r)-pramipexole |
WO2008079404A2 (en) | 2006-12-22 | 2008-07-03 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
US20100316712A1 (en) | 2006-12-22 | 2010-12-16 | Combinatorx, Incorporated | Pharmaceutical compositions for treatment of parkinson's disease and related disorders |
US20100016328A1 (en) | 2007-01-12 | 2010-01-21 | Biomarin Pharmaceutical, Inc. | Pterin analogs |
US20120022072A1 (en) | 2007-01-12 | 2012-01-26 | Biomarin Pharmaceutical Inc. | Pterin analogs |
WO2008089008A2 (en) | 2007-01-12 | 2008-07-24 | Biomarin Pharmaceutical Inc. | Tetrahydrobiopterin prodrugs |
US20090326062A1 (en) | 2007-02-13 | 2009-12-31 | Chemo Iberica, SA | Process for preparing entacapone substantially free of z-isomer, synthesis intermediates thereof and a new crystalline form |
WO2008098960A1 (en) | 2007-02-13 | 2008-08-21 | Chemo Iberica, S. A. | Process for preparing entacapone substantially free of z-isomer, synthesis intermediates thereof and a new crystalline form |
WO2008113056A2 (en) | 2007-03-14 | 2008-09-18 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
US20140100372A1 (en) | 2007-03-14 | 2014-04-10 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
US20080227985A1 (en) | 2007-03-14 | 2008-09-18 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazoles |
US20110230514A1 (en) | 2007-05-01 | 2011-09-22 | Concert Pharmaceuticals Inc. | Morphinan Compounds |
WO2008137474A1 (en) | 2007-05-01 | 2008-11-13 | Concert Pharmaceuticals Inc. | Morphinan compounds |
US20080280936A1 (en) | 2007-05-01 | 2008-11-13 | Concert Pharmaceuticals Inc. | Morphinan Compounds |
EP1997493A1 (en) | 2007-05-28 | 2008-12-03 | Laboratorios del Dr. Esteve S.A. | Combination of a 5-HT7 receptor ligand and an opioid receptor ligand |
WO2009002297A1 (en) | 2007-06-22 | 2008-12-31 | Gluconova Llc | Halide-free glucosamine-acidic drug complexes |
US20090075942A1 (en) | 2007-09-13 | 2009-03-19 | Protia, Llc | Deuterium-enriched fosamprenavir |
CN101390854A (en) | 2007-09-21 | 2009-03-25 | 北京德众万全药物技术开发有限公司 | Medical composition containing riluzole |
WO2009056791A1 (en) | 2007-11-02 | 2009-05-07 | Pliva Hrvatska D.O.O. | Processes for preparing pharmaceutical compounds |
US20090118365A1 (en) | 2007-11-06 | 2009-05-07 | Xenoport, Inc | Use of Prodrugs of GABA B Agonists for Treating Neuropathic and Musculoskeletal Pain |
WO2009061934A1 (en) | 2007-11-06 | 2009-05-14 | Xenoport, Inc. | Use of prodrugs of gaba b agonists for treating neuropathic and musculoskeletal pain |
CN101186583A (en) | 2007-12-20 | 2008-05-28 | 吉林大学 | Methyl 2-(2-(2,6-dichlorophenylamino)phenyl)acetate and its synthesizing method and application |
US20100081713A1 (en) | 2008-03-19 | 2010-04-01 | CombinatoRx, (Singapore) Pte. Ltd. | Compositions and methods for treating viral infections |
CN101569618A (en) | 2008-04-30 | 2009-11-04 | 上海医药工业研究院 | Application of long-chain fatty acid derivative or plant extracts containing same in inhibiting the activity of aromatizing enzyme |
EP2298777A2 (en) | 2008-06-09 | 2011-03-23 | Enzytech, Ltd. | Method for preparing clopidogrel and its derivatives |
US20110087028A1 (en) | 2008-06-09 | 2011-04-14 | Enzytech Ltd. | Method for preparing clopidogrel and its derivatives |
CN102149673A (en) | 2008-07-08 | 2011-08-10 | 凯特贝希制药公司 | Fatty acid acetylated salicylates and their uses |
US20100184730A1 (en) * | 2008-07-08 | 2010-07-22 | Vu Chi B | Fatty Acid Acylated Salicylates and Their Uses |
CN102123763A (en) | 2008-08-19 | 2011-07-13 | 什诺波特有限公司 | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
US20120095003A1 (en) | 2008-08-19 | 2012-04-19 | Xenoport, Inc. | Methods of using prodrugs of methyl hydrogen fumarate and pharmaceutical compositions thereof |
US20120157523A1 (en) | 2008-08-19 | 2012-06-21 | Xenoport, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
US8778991B2 (en) | 2008-08-19 | 2014-07-15 | Xenoport, Inc. | Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use |
US20110229561A1 (en) | 2008-08-22 | 2011-09-22 | Ritesh Kapoor | Extended Release Pharmaceutical Composition Of Entacapone Or Salts Thereof |
WO2010020969A1 (en) | 2008-08-22 | 2010-02-25 | Wockhardt Research Centre | An extended release pharmaceutical composition of entacapone or salts thereof |
US20130274306A1 (en) | 2008-09-18 | 2013-10-17 | Bioalliance Pharma S.A. | Treating inflammation and inflammatory pain in mucosa using mucosal prolonged release bioadhesive therapeutic carriers |
US20150148398A1 (en) | 2008-09-18 | 2015-05-28 | Bioalliance Pharma S.A. | Treating inflammation and inflammatory pain in mucosa using mucosal prolonged release bioadhesive therapeutic carriers |
WO2010031819A1 (en) | 2008-09-18 | 2010-03-25 | Bioalliance Pharma | Treating inflammation and inflammatory pain in mucosa using mucosal prolonged release bioadhesive therapeutic carriers. |
US20110288140A1 (en) | 2008-09-18 | 2011-11-24 | Bioalliance Pharma ,S.A. | Treating inflammation and inflammatory pain in mucosa using mucosal prolonged release bioadhesive therapeutic carriers |
US20110313176A1 (en) | 2008-12-26 | 2011-12-22 | Actavis Group Ptc Ehf | Processes for preparing highly pure rotigotine or a pharmaceutically acceptable salt thereof |
WO2010115252A1 (en) | 2009-04-06 | 2010-10-14 | Ems S.A. | PHTHALIMIDE DERIVATIVES OF NON-STEROIDAL ANTI-INFLAMMATORY COMPOUNDS AND/OR TNF-α MODULATORS, METHOD FOR PRODUCING SAME, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME AND USES THEREOF FOR THE TREATMENT OF INFLAMMATORY DISEASES |
US20120115817A1 (en) | 2009-04-06 | 2012-05-10 | Ems S.A. | Phthalimide derivatives of non-steroidal anti-inflammatory compounds and/or tnf-alpha modulators, method for producing same, pharmaceutical compositions containing same and uses thereof for the treatment of inflammatory diseases |
US20120093922A1 (en) | 2009-04-29 | 2012-04-19 | Amarin Corporation Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
US20140155455A1 (en) | 2009-04-29 | 2014-06-05 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
WO2010127099A2 (en) | 2009-04-29 | 2010-11-04 | Amarin Corporation Plc | Pharmaceutical compositions comprising epa and a cardiovascular agent and methods of using the same |
WO2010147666A1 (en) | 2009-06-19 | 2010-12-23 | Memorial Sloan-Kettering Cancer Center | Compounds useful as carbonic anhydrase modulators and uses thereof |
US20120208850A1 (en) | 2009-08-10 | 2012-08-16 | Bellus Health Inc. | Methods, compounds, and compositions for delivering 1,3-propanedisulfonic acid |
WO2011017800A1 (en) | 2009-08-10 | 2011-02-17 | Bellus Health (International) Limited | Methods, compounds, and compositions for delivering 1,3-propan ed isulfonic acid |
CN102002053A (en) | 2009-09-02 | 2011-04-06 | 陕西合成药业有限公司 | Tetrahydro thienopyridine derivative for treating |
CN101717392A (en) | 2009-10-09 | 2010-06-02 | 苏州凯达生物医药技术有限公司 | Method for preparing rotigotine and derivative thereof |
CN102050815B (en) | 2009-11-06 | 2014-04-02 | 北京美倍他药物研究有限公司 | Dabigatran ester derivatives as prodrug |
CN101724934A (en) | 2009-11-10 | 2010-06-09 | 东华大学 | Medicinal fibre used for treating cutaneous inflammation and pain, preparation and application thereof |
WO2011060945A2 (en) | 2009-11-20 | 2011-05-26 | Gp Pharm, S.A. | Capsules of active pharmaceutical ingredients and polyunsaturated fatty acid esters for the treatment of cardiovascular diseases |
US20130065909A1 (en) | 2010-01-08 | 2013-03-14 | Catabasis Pharmaceuticals, Inc. | Fatty acid fumarate derivatives and their uses |
US20110172240A1 (en) | 2010-01-08 | 2011-07-14 | Milne Jill C | Fatty acid fumarate derivatives and their uses |
WO2011085211A1 (en) | 2010-01-08 | 2011-07-14 | Catabasis Pharmaceuticals, Inc. | Fatty acid fumarate derivatives and their uses |
WO2011089216A1 (en) | 2010-01-22 | 2011-07-28 | Ascendis Pharma As | Dipeptide-based prodrug linkers for aliphatic amine-containing drugs |
RU2436772C2 (en) | 2010-01-28 | 2011-12-20 | Закрытое акционерное общество "НПК ЭХО" | 4[(4'-nicotinoylamino)butyroylamino]butanoic acid, exhibiting nootropic activity, and method of producing said compound |
US20130190327A1 (en) | 2010-02-26 | 2013-07-25 | Catabasis Pharmaceuticals Inc | Bis-fatty acid conjugates and their uses |
WO2011106688A1 (en) | 2010-02-26 | 2011-09-01 | Catabasis Pharmaceuticals, Inc. | Bis-fatty acid conjugates and their uses |
JP5412340B2 (en) | 2010-03-19 | 2014-02-12 | 本田技研工業株式会社 | Vehicle viewing window |
WO2011154833A1 (en) | 2010-06-08 | 2011-12-15 | Mahesh Kandula | Cysteamine derivatives and their use in the treatment of nash |
US20110300190A1 (en) | 2010-06-08 | 2011-12-08 | Krisani Biosciences (P) Ltd | Compound, composition and uses thereof |
WO2012007352A1 (en) | 2010-07-12 | 2012-01-19 | Boehringer Ingelheim International Gmbh | Aqueous composition comprising bromhexine |
US20130267605A1 (en) | 2010-07-12 | 2013-10-10 | Uwe Scheuring | Aqueous composition comprising bromhexine |
US20120046272A1 (en) | 2010-08-23 | 2012-02-23 | Grunenthal Gmbh | Novel Therapeutic Compounds |
WO2012025213A2 (en) | 2010-08-23 | 2012-03-01 | Grünenthal GmbH | Novel therapeutic compounds |
WO2012027543A1 (en) | 2010-08-25 | 2012-03-01 | Teva Pharmaceuticals Usa, Inc. | Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof |
CN101921245A (en) | 2010-08-30 | 2010-12-22 | 中国人民解放军军事医学科学院卫生学环境医学研究所 | Sulfonamides compound for inhibiting carbonic anhydrase II and synthesis method and application thereof |
US20130217737A1 (en) | 2010-10-29 | 2013-08-22 | Al-Giax Pharmaceuticals Gmbh | Use of Malononitrilamides in Neuropathic Pain |
WO2012055567A2 (en) | 2010-10-29 | 2012-05-03 | Algiax Pharmaceuticals Gmbh | Use of malononitrilamides in neuropathic pain |
EP2450039A1 (en) | 2010-11-08 | 2012-05-09 | PAION UK Ltd. | Dosing regimen for sedation with CNS 7056 (Remimazolam) |
US20140080815A1 (en) | 2010-11-08 | 2014-03-20 | Paion Uk Ltd. | Dosing regimen for sedation with cns 7056 (remimazolam) |
WO2012115695A1 (en) | 2011-02-25 | 2012-08-30 | Catabasis Pharmaceuticals, Inc. | Bis-fatty acid conjugates and their uses |
WO2013008182A1 (en) | 2011-07-10 | 2013-01-17 | Mahesh Kandula | Prodrugs of gaba analogs |
CN102336767A (en) | 2011-07-11 | 2012-02-01 | 华东理工大学 | Method for preparing high-purity chiral alpha-substituted-6,7-thiaindan[3,2-c]pyridine derivative |
WO2013017974A1 (en) | 2011-07-30 | 2013-02-07 | Mahesh Kandula | Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases |
WO2013024376A1 (en) | 2011-08-16 | 2013-02-21 | Mahesh Kandula | Compositions and methods for the treatment of atherothrombosis |
WO2013027150A1 (en) | 2011-08-21 | 2013-02-28 | Mahesh Kandula | Compositions and methods for the treatment of parkinson's disease |
WO2013152608A1 (en) | 2012-04-10 | 2013-10-17 | 凯莱英医药集团(天津)股份有限公司 | Method for synthesizing sapropterin dihydrochloride |
CN102633799A (en) | 2012-04-10 | 2012-08-15 | 凯莱英医药集团(天津)股份有限公司 | Method for synthesizing sapropterin dihydrochloride from racemate intermediate separation route |
WO2013167993A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of neurological degenerative disorders |
WO2013168022A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for treating atherothrombosis |
WO2013167988A1 (en) | 2012-05-08 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of cough |
WO2013167996A1 (en) | 2012-05-10 | 2013-11-14 | Mahesh Kandula | Compositions and methods for the treatment of metabolic syndrome |
WO2013175377A2 (en) | 2012-05-23 | 2013-11-28 | Mahesh Kandula | Compositions and methods for the treatment of mucositis |
WO2014174425A3 (en) | 2013-04-24 | 2015-02-19 | Mahesh Kandula | Compositions and methods for the treatment of orthostasis and neurological diseases |
US8952068B2 (en) | 2013-06-04 | 2015-02-10 | Mahesh Kandula | Compositions for the treatment of diabetes and pre-diabetes |
Non-Patent Citations (33)
Title |
---|
"1H and 13C Nuclear Magnetic Resonance Studies on the Tautomerism, Geometrical Isomerism and Conformation of some Cyclic Amidines, Guanidines and Related Systems", Journal of American Chemical Society, May 1975, by Lloyd M. Jackman et al. (p. 1) http://pubs.acs.org/doi/pdf/10.1021/ia00843a033. |
"Advances in Prodrug Design", Mini-Reviews in Medical Chemistry, 2005, 5 pp. 893-914 by Silva AT et al. (pp. 22). |
"Amidines and related compounds. 6. Studies on structure-activity relationships of antihypertensive and antisecretory agents related to clonidine", US National Library of Medicine National Institutes of HealthSearch database, Jan. 1975, by Jen T et al. (p. 1) http://www.ncbi.nlm.nih.gov/pubmed/234014?report=abstract. |
"Anticonvulsant O-Alkyl Sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose Sulfamate and Related Compounds", Journal of Medicinal Chemistry, 1987, vol. 30, No. 5, 880-887 by Bruce E. Maryanoff et al. (pp. 8). |
"Anticonvulsant O-Alkyl Sulfamates. 2,3:4,5-Bis-O-(1-methylethylidene)-β-D-fructopyranose Sulfamate and Related Compounds", Journal of Medicinal Chemistry, 1987, vol. 30, No. 5, 880-887 by Bruce E. Maryanoff et al. (pp. 8). |
"Antioxidant and Radical Scavenging Properties of 8-Oxo Derivatives of Xanthine Drugs Pentoxifylline and Lisofyllin", Biochemical and Biophysical Research Communications, vol. 288, Issue 5, Nov. 16, 2001 by Vadiraja B. Bhat et al. (p. 1) http://www.sciencedirect.com/science/article/pii/S0006291X01959224. |
"Biochemical and Biophysical Research Communications", Database CAPLUS on STN, Acc. No. 2009:265795, (2009), 380(3), pp. 586-590, by Yamada et al. (pp. 3). |
"Bioisosteres/Isosteres", Bryn Mawr College, 2006 (pp. 2). |
"Burger's Medicinal Chemistry and Drug Discovery", Fifth Edition, vol. 1: Principles and Practice, Feb. 8, 1995 by Manfred E. Wolff (pp. 4). |
"Cancer Treatment-Induced Mucositis Pain: Strategies for Assessment and Management", Therapeutics and Clinical Risk Management, vol. 2(3): 251-258, Sep. 2006 by Debra J Harris (pp. 8) http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1936261/. |
"Drug Discovery Today", vol. 13, pp. 21-22 in Nov. 2008 by Stefan Schafer et al. (pp. 4). |
"Effect of pentoxifylline and/or alpha lipoic acid on experimentally induced acute pancreatitis.", European Journal of Pharmacology, Jun. 21, 2010 by Amany A. Abdin et al. (p. 1) http://www.ncbi.nlm.nih.gov/pubmed/20599924. |
"Enantioseparation of anaesthetic drugs by capillary zone electrophoresis using cyclodextrin-containing background electrolytes", Electrophoresis, 19, 731-737, May 1998 by Ahmad Amini et al. (p. 7). |
"Enzyme-catalyzed regioselective synthesis of lipophilic guaifenesin ester derivatives", Journal of Molecular Catalysis B: Enzymatic, vol. 27, Issues 2-3, Feb. 2, 2004, pp. 97-102 by Na Wang et al. (p. 1) http://www.sciencedirect.com/science/article/pii/S1381117703002650. |
"From bench to clinic and back", Perspective on the 1st IQPC Translation Research conference, Journal of Translational Medicine, Dec. 20, 2004 by Heidi Horig et al. (pp. 8). |
"Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant alpha-lipoic acid on insulin resistance in the obese Zucker rat", Metabolism, vol. 57, Issue 10, Oct. 2008, pp. 1465-1472 by Elizabeth A. Muellenbach et al. (p. 1) http://www.sciencedirect.com/science/article/pii/S0026049508002047. |
"Interactions of the advanced glycation end product inhibitor pyridoxamine and the antioxidant α-lipoic acid on insulin resistance in the obese Zucker rat", Metabolism, vol. 57, Issue 10, Oct. 2008, pp. 1465-1472 by Elizabeth A. Muellenbach et al. (p. 1) http://www.sciencedirect.com/science/article/pii/S0026049508002047. |
"Modern Pharmaceutics", Third Edition, Marcel Dekker, Inc. New York, 1996 by Gilbert S. Banker et al. (pp. 3). |
"N-Acylcysteamines", CAPLUS 1959:121370 by Tozaburo Kurihara et al. (p. 1). |
"Nicotinamide-substituted complexes as redox markers. 1. Synthesis and UV investigation of rhenium and technetium mixed-ligand systems", Journal of Labelled Compounds, Jan. 1998 by T. Kniess et al. (p. 1) http://www.researchgate.net/publication/243806712-Nicotinamide-substituted-complexes-as-redox-markers.-1.Synthesis-and-UV-investigation-of-rhenium-and-technetium-mixed-ligand-systems. |
"Palladium-Catalyzed Direct Arylation of Benzoxacoles with Unactivated Simple Arenes", Electronic Supplementary Material (ESI) for Chemical Communications, Sep. 14, 2012, by Ge Wu et al. (pp. 84) http://www.rsc.org/suppdata/cc/c2/c2cc34238c/c2cc34238c.pdf. |
"Pretreatment with pentoxifylline and N-acetylcysteine in liver ischemia reperfusion-induced renal injury.", Renal Failure, Feb. 27, 2012, by Behjat Seifi et al. (p. 1) http://www.ncbi.nlm.nih.gov/pubmed/22364443. |
"Progress Application of Fumaric Acid and the Derivatives of Fumaric Acid,Guangdong Chemical Industry", Guangdong Chemical Industry, Jul. 31, 2007, by Gao Cuiying1 et al. (p. 1) http://en.cnki.com.cn/Article-en/CJFDTOTAL-GDHG200707027.htm. |
"Recent Advances in the Mechanism of Pyridoxine responsive Disorders", Journal of Inherited Metabolic Disorder, 1985 by B. Fowler et al. (pp. 8). |
"Tafamidis", from Nature Review Drug Discovery 11, Mar. 2012 by Gerard Said et al. (pp. 2) http://www.nature.com/nrd/journal/v11/n3/full/nrd3675.html. |
"The role of structural information in the discovery of direct thrombin and factor Xa inhibitors", Trends in Pharmacological Sciences, vol. 33, Issue 5, Apr. 2012 (p. 1) http://www.cell.com/trends/pharmacological-sciences/abstract/S0165-6147(12)00036-3. |
Probing the skin permeation of fish oil EPAand ketoprofen 1. NMR spectroscopy and molecular modelling, International Journal of Pharmaceutics, vol. 338, Issues 1-2, Jun. 29, 2007, pp. 207-212 by Christopher P. Thomas et al. (pp. 2) http://www.sciencedirect.com/science/article/pii/S0378517307001330. |
RN 67195-24-8 Registry Entered STN: Nov. 16, 1984 (pp. 2) http://chem.sis.nlm.nih.gov/chemidplus/rn/67195-24-8. |
Screenshot of 'Bioisostere' on Wikipedia, Aug. 25, 2015 (pp. 2). |
Synthesis and evaluation of Ketorolac ester prodrugs for transdermal delivery,Journal of Pharmaceutical Science, by Hea-Jeong Doh et al. May 2003 (p. 1) http://onlinelibrary.wiley.com/doi/10.1002/jps.10353/abstract. |
Synthesis of alpha4-N-acyl pyridoxamines and hydrolysis of alpha4-N-octanoyl pyridoxamine, Fac. Pharm. Sci., Mukogawa Women's University., Nishinomiya, Japan, in 1976, 50, 85-91 by Mizuno et al. (pp. 2). |
Synthesis of α4-N-acyl pyridoxamines and hydrolysis of α4-N-octanoyl pyridoxamine, Fac. Pharm. Sci., Mukogawa Women's University., Nishinomiya, Japan, in 1976, 50, 85-91 by Mizuno et al. (pp. 2). |
Tamoxifen: A Most Unlikely Pioneering Medicine, Natures Review: Drug Discovery, vol. 2, Mar. 2003 by V. Craig Jordan (pp. 9). |
Also Published As
Publication number | Publication date |
---|---|
US20160120839A1 (en) | 2016-05-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9434704B2 (en) | Compositions and methods for the treatment of neurological degenerative disorders | |
US9498461B2 (en) | Compositions and methods for the treatment of inflammatory bowel disease | |
US20150133533A1 (en) | Compositions and methods for the treatment of cough | |
US9492409B2 (en) | Compositions and methods for the treatment of local pain | |
US9403793B2 (en) | Compositions and methods for the treatment of moderate to severe pain | |
US20220162156A1 (en) | Compositions and methods for the treatment of irritable bowel syndrome | |
US9403826B2 (en) | Compositions and methods for the treatment of inflammatory disorders | |
US10774059B2 (en) | Compositions and methods for the treatment of inflammation | |
US20150210667A1 (en) | Compositions and methods for the treatment of autonomic and other neurological disorders | |
US20150218136A1 (en) | Compositions and methods for the treatment of neurologic diseases | |
US9333187B1 (en) | Compositions and methods for the treatment of inflammatory bowel disease | |
US10208014B2 (en) | Compositions and methods for the treatment of neurological disorders | |
US9403857B2 (en) | Compositions and methods for the treatment of metabolic syndrome | |
WO2015028976A2 (en) | Compounds and methods for the treatment of inflammatory diseases | |
US20150111966A1 (en) | Compositions and methods for the treatment of fibromyalgia pain | |
US20220048850A1 (en) | Compositions and methods for the treatment of inflammation | |
US9321775B2 (en) | Compositions and methods for the treatment of moderate to severe pain | |
US20150141384A1 (en) | Compositions and methods for the treatment of neurological degenerative disorders | |
US9394288B2 (en) | Compositions and methods for the treatment of asthma and allergy | |
US9399634B2 (en) | Compositions and methods for the treatment of depression | |
US9266823B2 (en) | Compositions and methods for the treatment of parkinson's disease | |
US20150087697A1 (en) | Compositions and methods for the treatment of muscle pain | |
US20150141513A1 (en) | Compositions and methods for the treatment of neurological degenerative disorders and neurological diseases | |
WO2015001499A2 (en) | Compositions and methods for the treatment of irritable bowel syndrome and the associated abdominal cramping | |
US20150126568A1 (en) | Compositions and methods for the treatment of hypertension and management of diabetic kidney disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: CELLIX BIO PRIVATE LIMITED, INDIA Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:KANDULA, MAHESH;REEL/FRAME:038007/0557 Effective date: 20160317 |
|
STCF | Information on status: patent grant |
Free format text: PATENTED CASE |
|
MAFP | Maintenance fee payment |
Free format text: PAYMENT OF MAINTENANCE FEE, 4TH YR, SMALL ENTITY (ORIGINAL EVENT CODE: M2551); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY Year of fee payment: 4 |
|
FEPP | Fee payment procedure |
Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: SMALL ENTITY |